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ABSTRACT

REGULATION OF ROD PHOTORECEPTOR PHOSPHODIESTERASE
(PDE6) BY THE GLUTAMIC ACID-RICH PROTEIN 2 (GARP2)

by
Dana C. Pentia
University of New Hampshire, September, 2006

Rod photoreceptor phosphodiesterase (PDE6), the central enzyme of visual
transduction in vertebrate photoreceptors, associates with the disk membranes of the rod
outer segment (ROS) of the photoreceptor cell. This association insures the high
efficiency of activation by the G-protein, transducin, and the precise control of its
inactivation. In addition to binding to transducin during visual excitation, PDE6 is
hypothesized to be regulated by other interacting proteins.
The first aim of this research was to isolate and identify the proteins that interact
with PDE6 during various stages of the visual signaling pathway. We evaluated methods
for solubilizing PDE6 and its binding partners from the ROS disk membrane, and
analyzed the protein composition by immunoprecipitation or size exclusion
chromatography. Our results suggested that additional, as-yet unidentified, proteins bind
to PDE6 in its nonactivated and activated states. This work led to enhanced protocols for
purifying rod and cone PDE6 from photoreceptor cells.

xi
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The second aim of the study was to evaluate the importance of the Glutamic AcidRich Protein-2 (GARP2) as a PDE6-interacting protein. First, we confirmed earlier
observations that GARP2 is a high-affinity PDE6 interacting protein, and is present in
amounts sufficient to stoichiometrically bind PDE6. Addition of purified GARP2 to ROS
membranes containing PDE6 demonstrated that it is able to inhibit the basal activity of
the nonactivated PDE6 holoenzyme. In contrast with a previous report, GARP2 does not
alter the ability of transducin to activate PDE6. These results suggest a role for GARP2 in
reducing the spontaneous activation of dark-adapted PDE6, thereby serving to increase
the light sensitivity of rod photoreceptors as “single photon detectors.”
The final aim Was to investigate the molecular mechanism by which GARP2
interacts with PDE6 and regulates its catalytic properties. We found that GARP2 exerted
a destabilizing effect on the regulatory cGMP binding sites of the PDE6 catalytic dimer,
as well as interacting directly with two distinct subdomains of the inhibitory subunit of
PDE6. These latter interactions are believed to account for the observed ability of
GARP2 to enhance the affinity of the inhibitory subunits for the catalytic dimer of PDE6.

xii
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CHAPTER 1

INTRODUCTION1

1. Photoreceptor Cells and Visual Transduction in Vertebrates.
In vertebrates, vision starts in specialized neuronal cells located in the retina: rods
and cones. Rods are significantly larger in the vertebrate retina, and more abundant than
cones (see. Figl.l.). In mammalian retina, cones are grouped in a central region named

Figure 1.1. Electron microscopy
visualization of rods and cones
1The abbreviations used are: PDE6, photoreceptor phosphodiesterase; Py, inhibitory 10
kDa y subunit of PDE6; GARP2, glutamic acid-rich protein 2; PrBP-6,17 kDa prenylbinding protein; ROS, rod outer segment; Ta, G-protein, transducin, a subunit.
1
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fovea. The internal organization of photoreceptor cells consists of two major
compartments: the inner segment and the outer segment (Fig. 1.2.). The two subcellular
compartments are connected through a ciliary region. The inner segment contains all the
cellular machinery of a typical cell: the nucleus, mitochondria and other organelles. At
the end of the inner segment is the synaptic terminus which communicates the light
response to other retinal neurons.
The outer segment is the highly specialized part of the photoreceptor, having a
unique morphology and containing all the proteins involved in phototransduction. Rods
and cones outer segments have different wavelength specificity for light reception. Rods
are responsible for night vision, and function at low light intensities, being saturated at

Outer segment

Inner segment * « ,
r > '9 .

Nucleus

Axon

Synaptic b o #

Figure 1.2. Schematic representation of rod and
cone cell morphology

2
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high intensities of light. Cones are able to function in bright light, never saturate, and
provide color discrimination. While the major steps of phototransduction are similar in
rods and cones, morphological, physiological and biochemical differences exist between
rods and cones. At the morphological level, rods are usually longer than cones, and have
a rod-like shape. They are composed of distinct stacks of membranous disks surrounded
by plasma membrane. Cones, on the other hand, are generally shorter, having a cone-like
shape, and are formed by invaginations of the plasma membrane (see Fig. 1.2.).
All the components of visual transduction are localized in the outer segment of
the photoreceptor cells, attached to the disk membranes. Some proteins are
transmembrane proteins (rhodopsin, peripherin, etc.), other are attached to the membrane
via isoprenyl groups (transducin y, PDE a and p subunits), while others are fatty acylated
(transducin a, recoverin, etc.). The attachment of the isoprenylated proteins to the disk
membrane is believed to be facilitated by the prenyl-binding protein PrBP-8. The
structure of rod disk membranes is maintained by distinct proteins which connect the disk
rims to the plasma membrane (peripherin (Molday et al., 1987), GARP2 (Poetsch et al.,
2001)).

The visual pigment (rhodopsin for rods and cone opsins for cones) is a seventransmembrane segment receptor that resides in the outer segment membranes. The high
concentration of the pigment in these structures permits a high quantum efficiency of
photon capture. Physiologically, rods manifest a very sensitive response, being able to
detect single photons, while cones are less sensitive, generating electrical responses only
at higher intensities of light. Rods cannot however, effectively operate at high light

3
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intensities, whereas cones are able to generate a response even at the brightest light
intensities.
While the major phototransduction pathways are similar in rods and cones, the
differences in sensitivity and response kinetics are due to biochemical components of the
two photoreceptor cells. Rods and cones contain either different isoforms of the same
protein, or proteins that are unique to a specific photoreceptor type.

2. Activation Pathway of Visual Transduction.
The main phototransduction pathway serves to regulate cGMP levels in the outer
segment. Activation of the phototransduction pathway results in a decrease of the cGMP
concentration in the outer segment of the photoreceptor. The activation process starts
with the absorption of a photon by the visual receptor, rhodopsin. Rhodopsin is a seven

Disc Membrane

f c S f CaPlasma
Membrane

Transducin

Figure 1.3. Activation pathway of visual transduction.
Components of the visual excitation pathway are bound to the disk membranes. Light
activates rhodopsin (R), which will activate transducin by exchanging GDP for GTP.
The dissociated T a will interact with Py activating PDE6. The resulting drop in
cGMP concentration will determine the closure of the plasma membrane ion
channels. The Na+/K+/Ca2+ exchanger will pump Ca2+ Out of the cell, causing a drop
in the Ca2+ concentration as well.

4
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transmembrane protein, found in the outer segment disks. Upon light absorption, the
chromophore of the rhodopsin molecule (11-cis-retinal) is isomerized to all-trans-retinal.
This isomerization activates rhodopsin, which in turn activates the G-protein transducin.
Transducin is a heterotrimeric G protein. Its a-subunit (Ta) binds guanine nucleotides
and is anchored to the membrane by fatty acylation. The isoprenyl moiety on the y
subunit further anchores the tightly associated Py dimer (TPy) to the membrane. Upon
binding of TaPy to light-activated rhodopsin, the GDP bound to the a subunit is
exchanged for GTP. With GTP bound, Ta dissociates from TPy and interacts with the
inhibitory y subunit (Py) of the photoreceptor phosphodiesterase (PDE6). The inhibitory
constraint of Py is released upon interaction with activated Ta, such that PDE6 catalytic
activity is greatly accelerated. With the catalytic activity enhanced, PDE6 rapidly
converts cGMP to GMP, lowering the cGMP concentration inside the outer segment of
the photoreceptor. The decrease in intracellular cGMP concentration causes cGMP
dissociation from regulatory sites of the cGMP-gated channels on the plasma membrane.
This in turn causes the closure of the channels. This closing of the ion channels blocks
the flux of ions into the outer segment, and the plasma membrane becomes
hyperpolarized (see Fig. 1.3). This hyperpolarization is transmitted along the plasma
membrane from the outer segment to the synaptic terminus of the photoreceptor neuron,
where the signal is transmitted to other retinal neurons.

5
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3. Inactivation of Visual Excitation.
The inactivation of the visual transduction cascade is not the reverse of its

♦ [CCT ]

Figure 1.4. The inactivation pathway of rhodopsin (R).
The decrease in Ca2+ concentration determines the release of rhodopsin
kinase (Rk) form recoverin (Rec), and phosphorylation of rhodopsin, which
will allow the binding of arrestin (Arr) and inhibition of activated rhodopsin.

activation. A different set of regulatory proteins control the events of inactivation. In
order for the photoreceptor to detect changes in the ambient light, it needs to rapidly
return to the non-activated physiological state in order to process another set of absorbed
photons. Therefore each of the activation steps is inactivated by its own set of processes.
Activated rhodopsin is rapidly phosphorylated by rhodopsin kinase (Mendez et al., 2000;
Kennedy et al., 2001; Ohguro, 2000; Ohguro et al., 1996) which allows arrestin to bind
with high affinity and inactivate it (Vishnivetskiy et al., 1999; Gurevich and Gurevich,
2004; Krupnick and Benovic, 1998; Wilden, 1995). Arrestin binding to rhodopsin
disrupts the interaction that rhodopsin makes with transducin (see Fig. 1.4 ).

6
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Transducin has its own inactivation pathway, independent of rhodopsin
inactivation. It is inactivated when bound GTP is hydrolyzed to GDP. The a subunit of

Figure 1.5. Inactivation of transducin.
Bound GTP is hydrolyzed to GDP by the intrinsic GTPase activity of Ta
enhanced by the GAP proteins RGS9, Gp5L and Py.
transducin has an intrinsic GTPase activity (Fung et al., 1981), but the rate of hydrolysis
is slow (Sitaramayya and Liebman, 1983). To speed the rate of transducin inactivation,
GTPase accelerating proteins interact with Ta (see Fig. 1.5.). The protein complex that
accelerates the hydrolysis rate of GTP is composed of RGS9 (regulator of G protein
signaling protein 9), Gp5 (He et al., 1998; Makino et al., 1999; Slep et al., 2001), the
transmembrane protein R9AP [not shown in Fig. 1.5.; (Hu and Wensel, 2002)], as well as
the inhibitory Py subunit of PDE6 (Slepak et al., 1995; Cote et al., 1994). The transducinactivated PDE6 is inhibited only after Ta hydrolyses its bound GTP and reforms the
transducin heterotrimer. The inhibitory Py subunit is then able to restore the inhibited
state of the PDE6 catalytic subunits.
So far, there is no known mechanism that directly inactivates PDE6, and is
independent of transducin inactivation. It is possible that other mechanisms control PDE6
activity at the level of Py inhibition. For example, it is known that Py can be

7
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phosphorylated (Paglia et al., 2002; Udovichenko et al., 1994; Xu et al., 1998) and ADPribosilated (Bondarenko et al., 1997; Bondarenko et al., 1999). Both modifications could
directly influence PDE6 catalytic activity. PDE6 activity is also indirectly influenced by
Ca2+ regulatory mechanisms (discussed below) that control intracellular cGMP levels.
Finally, there is physiological evidence that novel proteins or pathways may regulate
PDE6. A major portion of the thesis is devoted to exploring a novel regulatory
mechanism involving GARP2.

4. Biochemistry of Recovery and Adaptation (Ca2+. cGMPl.
As described above, light activation causes a decrease in cGMP. The termination
reactions restore the inhibited state of PDE6, and lead to the recovery of cGMP levels.
For the restoration of cGMP levels, a new set of events takes place. The enzyme
responsible for restoring cGMP level is guanylate cyclase (GC). The activity of this
enzyme is regulated by Ca levels in the outer segment. As stated earlier, light activation
causes closure of the cGMP-gated channels in the plasma membrane, preventing the
entry of both Na+ and Ca2+ ions inside the outer segment of the photoreceptor. At the
same time Ca2+ is being transported out of the cell through the Na+/Ca2+/K+ exchanger
located on the plasma membrane (Hodgkin et al., 1987). The resulting low intracellular
Ca2+ concentration causes dissociation of Ca2+ from Ca2+ binding protein GCAP
(guanylate cyclase activating protein) which stimulates guanylate cyclase activity
(Palczewski et al., 2004). By elevating the cGMP levels, the dark-adapted state of the
photoreceptor is rapidly restored.

8
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The synthesis of cGMP by guanylate cyclases also contributes to desensitizing the
photoreceptor cell in response to constant illumination conditions. Photoreceptor cells
need to function over a wide range of light intensities. To generate an electrical response
to an incremental change in illumination intensity, photoreceptors must adapt their light
sensitivity. A major regulator of light adaptation is the intracellular messenger Ca2+. One
mechanism of adaptation mediated by Ca is the regulation of guanylate cyclase activity
by GCAPs during extended illumination. The combination of PDE6 activation and GC
activation causes an increase in cGMP metabolic flux, which represents one mechanism
for light adaptation.
Another mechanism of adaptation which is controlled by Ca2+ concentration is the
activation of rhodopsin kinase. When the Ca2+ concentration is high, rhodopsin kinase is
bound to the Ca2+ binding protein recoverin, and the activity of rhodopsin kinase is
inhibited (Kawamura, 1993; Gorodovikova et al., 1994; Klenchin et al., 1995; Chen et al.,
1995). When the Ca2+ concentration drops following excitation, recoverin is not longer
complexed with Ca2+, and is released from rhodopsin kinase (Gray-Keller et al., 1993;
Koutalos and Yau, 1996). Activated rhodopsin kinase then phosphorylates rhodopsin,
which in turn induces arrestin binding, and blocks the excitation pathway (Fig. 1.4.).
Another adaptative mechanism regulated by Ca2+ concentration is the affinity of the
cGMP gated channel for cGMP. In a high Ca condition, the cGMP-gated channel is
bound to the calcium binding protein, calmodulin (Hsu and Molday, 1993; Nakatani et
al., 1995; Bauer, 1996). The affinity of the cGMP-gated channel for cGMP is greatly
increased upon the dissociation of calmodulin which occurs when the Ca2+ levels are low.

9
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The increased affinity for cGMP allows the channels to stay open at lower cGMP
concentrations during light adaptation.
There are numerous other mechanisms of adaptation which are currently studied.
Some of these mechanisms involve photopigment bleaching (more pronounced in cones
(Rodieck, 1998; Burkhardt, 1994), Ca2+ buffering by Ca2+ binding proteins (Korenbrot
and Rebrik, 2002), or translocation to the inner segment of the photoreceptor during
prolonged light illumination (Arshavsky, 2003).

5. Structure and Regulation of PDE6 Catalytic and Regulatory Domains.
PDE6 is one of eleven members of the super-family of cyclic nucleotide
phosphodiesterases. The preferred substrate for PDE6 is cGMP. In the PDE family PDE5
and PDE9 are also cGMP hydrolyzing enzymes (Soderling and Beavo, 2000; Francis et
al., 2001), while PDE2, PDE3, PDE4, PDE7 and PDE8 are prefer cAMP as substrate
(Soderling and Beavo, 2000). PDE1, PDE10 and PDE11 can hydrolyze with equal
efficiency both cGMP and cAMP (Soderling and Beavo, 2000) (Kakkar et al., 1999).
Each PDE family has its predominant tissue location, such as brain (PDE1, PDE2, PDE7
and PDE10), heart (PDE1, PDE2, PDE3, and PDE5), liver (PDE2), intestine (PDE9),
smooth muscle (PDE5), skeleton muscle (PDE7 and PDE 10), thyroid gland (PDE8),
spleen (PDE9), prostate (PDE11), olfactory cells (PDE1 and PDE7), adipose tissue
(PDE3) (Soderling and Beavo, 2000). PDEs also differ in their regulatory mechanisms.
Many are regulated by phosphorylation (PDE1, PDE3, PDE4, PDE5), other are regulated
by GAF domains (named for their occurrence in cyclic GMP-regulated PDEs, Anabaena
adenylyl cyclases and the Escherichia coli transcription factor Fhl A) (PDE2, PDE5,

10
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PDE6, PDE10 and PDE11), and also by other mechanisms. PDE6 is the only PDE that is
regulated by another subunit, the inhibitory Py subunit (Hurley and Stryer, 1982).
Rod PDE6 is a heterotetramer, composed of two catalytic subunits (a and P), and
two identical inhibitory subunits (Py) (Fig.l.6.(Hurley and Stryer, 1982; Fung et al.,
1990; Artemyev et al., 1996b; Cote, 2003; Kajimura et al., 2002; Kameni Tcheudji et al.,

Figure 1.6. Structure of the rod PDE6.
The catalytic heterodimer is composed of the a and P
subunits, each of which contains a catalytic domain
(notch) and a cGMP-binding regulatory GAF domain.
The activity of PDE6 is inhibited by two identical
2001; Li et al., 1990).
Cone PDE6 is also believed to be a tetramer, but with two identical catalytic
subunits (a') and two identical inhibitory subunits (Py1) (Hurwitz et al., 1985; Gillespie
and Beavo, 1988).
The catalytic subunits of PDE6 are composed of two domains: a regulatory
domain and the catalytic domain. The regulatory domain is located in the N-terminal part
of the molecule, and is composed of two tandem GAF domains, GAFa and GAFb, one of
which binds cGMP. There are four potential cGMP binding sites within the GAF

11
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domains of the PDE6 catalytic dimer. However, only two of these sites bind cGMP, each
with differing affinity depending on the state of activation of PDE6 (Gillespie and Beavo,
1989; Cote et al., 1994; Mou et al., 1999). The GAFa domain is the primary dimerization
site for the PDE6 catalytic subunits (Kameni Tcheudji et al., 2001; Muradov et al., 2003).
Also, one site of interaction of the inhibitory Py subunit is located on the vicinity of
GAFa domain (Muradov et al., 2004), such that GAFa regulates the catalytic activity of
PDE6 through Py. A new study demonstrates that one Py binds asymmetrically to the
PDEaP catalytic dimer, at two sites at the GAF domains of the PDEap dimer (Guo et al.,
2005). One site of interaction is located at the GAF domain of the P catalytic subunit,
while the other is located at the GAF domain level of the a subunit of PDE6.
The catalytic domain of PDE6 has a strong sequence similarity with the catalytic
domain of PDE5 (McAllister-Lucas et al., 1993). However, the catalytic efficiency is
1000-fold greater for PDE6 (Granovsky and Artemyev, 2001) than it is for PDE5 which
is three orders of magnitude lower (Thomas et al., 1990). The catalytic pocket contains
divalent cations, with a high affinity binding site for Zn2+ for both PDE5 and PDE6
(Francis et al., 2000; Francis et al., 1994; He et al., 2000a). Most pharmacological
inhibitors of PDE5 are also effective inhibitors for PDE6 (Corbin and Francis, 2002;
Cote, 2004; Estrade et al., 1998; Luke et al., 2005; Marmor and Kessler, 1999; Zhang et
al., 2005b). The activation mechanism is different however for PDE6 and PDE5. While
PDE6 is activated by displacement of the inhibitory Py subunit (described above), PDE5
is activated by phosphorylation and allosteric regulation through its GAF domains
(Corbin et al., 2000; Rybalkin et al., 2003). The C-terminus of the catalytic subunit is

12
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isoprenylated, a feature unique to PDE6 that allows it to be membrane-bound
(Ovchinnikov et al., 1987; Lipkin et al., 1990; Li et al., 1990).

6. PDE6 Regulatory Proteins.
Other members of the PDE super-family are regulated allosterically through their
regulatory domains. For PDE6, the primary way of regulating the catalytic activity is
through interacting proteins.
The primary mean to regulate the catalytic activity of PDE6 results from the
interaction with its inhibitory Py subunit. Py is an 87 amino-acid protein (Ovchinnikov et
al., 1986; Hamilton and Hurley, 1990) which has the primary role in blocking the access
to the catalytic site (Granovsky et al., 1997). Py is classified as a natively unfolded
protein (Berger et al., 1997; Uversky, 2002). This is conferred by a limited secondary
structure (Slep et al., 2001), which allows the Py molecule to span distant parts of the

70

80

t

P-rich

a-h elical

GAFa interaction

active site

Figure 1.7. Structure of the inhibitory Py subunit.
In the C-terminal part is the proline-rich region and poly-cationic
(PC) region which interact with the GAFa domain on PDE6. The
N-terminal part interacts with the PDE6 catalytic site (CT) and
has a a-helical structure

catalytic subunit (Guo et al., 2005). To effectively inhibit PDE6 catalysis, Py binds to
PDE6 catalytic subunit at multiple sites. The highest binding affinity site of Py to PDE6
catalytic subunit is located in the vicinity of the GAFa domain of PDE6 (Natochin and
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Artemyev, 1996). Py has a complex structure (see Fig. 1.7.): the central region (a.a. 29-45)
contains a poly-cationic motif which serves as the high-affinity site of interaction with
activated transducin (Artemyev et al., 1992; Lipkin et al., 1988; Skiba et al., 1995;
Morrison et al., 1989; Brown, 1992). In the N-terminal region, Py also contains a prolinerich region (a.a. 20-28) which may serve as the site of interaction with SH3 domaincontaining proteins (Morin et al., 2003). The region of a.a. 20-45 also constitutes the
major interaction site with the GAFa domain of the catalytic subunit of PDE6 (Artemyev
et al., 1992; Lipkin et al., 1993; Natochin and Artemyev, 1996; Takemoto et al., 1992;
Mou and Cote, 2001). The Py subunit also has two phosphorylation sites at a.a. T22 and
T35 (Paglia et al., 2002; Udovichenko et al., 1993; Xu et al., 1998). The C-terminal
region also includes a site of interaction with transducin a (Ta).
The major site of interaction of Py with the catalytic site resides in the extreme Cterminus part (a.a. 83-87) (Brown, 1992; Lipkin et al., 1988). Upon transducin activation,
the inhibitory constraint of the C-terminal region of Py on the catalytic site is released by
Ta-GTP interacting with this region (Artemyev et al., 1992; Skiba et al., 1996). Py
dissociates from PDEap upon prolonged light activation. Upon dissociation Py has a
GTP-ase accelerating function, and together with RGS9 and Gp5-L regulates the GTPase function of T a (Arshavsky and Pugh, Jr., 1998; He et al., 2000b; Skiba et al., 1999).
Py also undergoes ADP-ribosylation at the central region (Arg and Arg ) when it is
free or in complex with PDEap dimer (Bondarenko et al., 1997; Bondarenko et al.,
1999). However, ADP-ribosylated Py can not make interaction with activated transducin
(Bondarenko et al., 1999).
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Another PDE6 interacting protein, the Prenyl-Binding Protein (PrBP-8) is
believed to have a role in the targeting of the isoprenylated PDE6 to the disk membrane
(see Fig. 1.8.) (Norton et al., 2005; Zhang et al., 2004). This protein was initially thought
to be a subunit of PDE6 because it co-purified with the soluble PDE6 (Florio et al., 1996;
Gillespie et al., 1989), but due to its low stoichiometry of binding to PDE6, it is not
considered a bona fide PDE6 subunit (Norton et al., 2005).
PrBP-8 has an immunoglobuline-like domain that forms a hydrophobic pocket
(Hanzal-Bayer et al., 2002). This pocket is able to bind to isoprenyl moieties and
solubilizes membrane bound protein (Cook et al., 2000; Marzesco et al., 1998; Zhang et
al., 2004).
In photoreceptor cells, PrBP-8 also interacts with rhodopsin kinases, small
GTPases such as Rabl3, Ras, Rap, and Rho6 (Zhang et al., 2005a). It is hypothesized that

Figure 1.8. Solubilization of PDE6 by PrBP-8 in vitro.
PrBP-8 binds to the isoprenyl moieties of the catalytic
subunits of PDE6 releasing it from the disk membranes.
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PrBP-5 is involved in the transport and membrane targeting of isoprenylated proteins
from their site of synthesis to the disk membranes of the outer segment (Norton et al.,
2005).
7. Structure, Localization and Role of GARP Proteins in Photoreceptor Cells.
The outer segment of rod photoreceptor cells contain a set of proteins that are not
found in cones. These proteins belong to the glutamic acid-rich protein family (GARPs).

G A R P’

G lu-rich

CaM

p ’ d o m ain

cGM P

channel p subunit
GARP1

GARP2

Figure 1.9. Structure of GARP proteins.
The N-terminal region contains the proline-rich repeats (R1-R4);
GARP1 and the P-subunit of the channel also have the glutamaterich domains (Glu-rich). The p-subunit of the channel has other
motifs such as a calmodulin binding domain (CaM), transmembrane
domains, (P' domain) and a cGMP binding domain.
The GARP family is composed of three proteins: two soluble proteins: GARP1 and
GARP2, and the N-terminal part of the p-subunit of the cGMP-gated plasma membrane
channel (see Fig.1.9.) (Ardell et al., 1995; Korschen et al., 1995; Sugimoto et al., 1991).
The GARP part of the cGMP gated channel faces the cytoplasm of the outer segment
(Colville and Molday, 1996). All three members of the GARP family are splice variants
of the same gene (Ardell et al., 1995). All three GARP proteins exhibit abnormal
migration of SDS-PAGE. It is believed that this is due to the high content of glutamate
residues which diminish the SDS binding to the protein (Korschen et al., 1995).

16

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

The amino-acid sequence of the three GARP proteins reveals some common
features. The first 291 amino-acids of all the GARP proteins are identical (Ardell et al.,
1996; Colville and Molday, 1996). The N-terminal region contains four proline-rich
repeats, which are also the most conserved regions among GARPs from different species
(Ardell et al., 1996; Colville and Molday, 1996; Korschen et al., 1995; Sugimoto et al.,
1991). One early hypothesis was that these proline-rich repeats favored protein-protein
interactions with PDE6, peripherin, guanylate cyclase, the a-subunit of the channel and
GARPs (Korschen et al., 1999). Further studies demonstrated however, that some of the
above-mentioned proteins are not interacting with the full-length GARPs, and only
peripherin, and other GARPs are binding to GARPs (Poetsch et al., 2001). Another
characteristic of the glutamic acid-rich proteins is the presence of the glutamic acid-rich
motif. However, this motif is present only in the P subunit of the cGMP-gated channel
and in GARP1; although GARP2 lacks this motif, the content of glutamate residues is
still high throughout the protein (Colville and Molday, 1996).

The last eight C-terminal amino-acids of GARP2 are unique, which serves as a
means to generate specific antibodies to GARP2 (Colville and Molday, 1996).
Immunolocalization studies with GARP2-specific antibodies show that it is localized
primarily at the rim of the outer segment disks, in close proximity with the plasma
membrane (Colville and Molday, 1996; Korschen et al., 1999). It has been proposed that
GARP2 serves as a structural bridge between the plasma membrane of the rod
photoreceptor and the disks (Poetsch et al., 2001). The sequence analysis of the GARP
proteins reveals another characteristic: the presence in high abundance of proline-
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glutamate-serine-threonine rich domains. These so-called PEST sequences are associated
with rapid degradation of the protein due to proteolysis (Rechsteiner and Rogers, 1996).
Recent study showed that GARP2 belongs to the family of "natively unfolded" proteins,
lacking a high degree of complexity of the secondary structure (Batra-Safferling et al.,
2006). This characteristic is usually associated with proteins that serve as scaffolds, and
GARP2 might serve as a structural protein preserving the integrity of the rod outer
segment (Batra-Safferling et al., 2006).
Another proposed role of GARP2 is as a regulator of PDE6 activity. Korschen et
al. (1999) showed that GARP2 is able to inhibit the activity of transducin-activated
PDE6, but has no effect on trypsin-activated or non-activated PDE6 activity. This finding
would suggest that GARP2 might serve as alternative mechanism of adaptive regulation
of the photoreceptor cells.

8. Hypotheses to be Tested.
The overall objective of this thesis is to identify and characterize alternative
mechanisms for regulation of PDE6 activity.
It is hypothesized that PDE6 is regulated by other mechanisms in addition to the
classical excitation pathway. These interactions may modulate PDE6 activity during later
stages of the visual process. The proteins that interact with PDE6 (Ta, Py) have shown a
regulatory effect on its catalytic activity. However, the rod photoreceptor contains other
proteins, some of which are present in low abundance, that might interact with PDE6 and
have an effect on the phototransduction pathway.
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The first goal of this research is to determine the PDE6 "interactome". The
different states of PDE6 activation may cause different proteins to associate and
dissociate. Therefore, each activation condition needs to be studied for the interacting
partners of PDE6. Once all of the binding partners for nonactivated and activated forms
of PDE6 are identified, the role of each individual protein can be determined.
A second major goal of this thesis is to more fully characterize the PDE6
interacting protein GARP2. A previous study showed that GARP2 interacts with PDE6
and reportedly regulates PDE6 in its transducin-activated state (Korschen et al., 1999).
This finding would suggest a role for GARP2 in desensitizing the visual excitation
pathway during bright light. This function of GARP2 to regulate PDE6 would only be
relevant to rod photoreceptors, since GARP2 is absent in cone photoreceptors. One
important difference in rod and cone photoresponse is their light sensitivity. Rods are
very sensitive, being able to respond to a single photon of light, while cones function
only at higher intensities of light. The higher sensitivity of rods results from a very low
dark "noise" of the photoreceptor, compared to cones that have a much higher
background "noise". My objective is to assess whether GARP2 regulates rod
photoreceptor activity in a way that would account for the different physiology of rods
versus cones.
In order to assess the physiological and biochemical significance of GARP2
binding to PDE6, it is necessary to determine the total amount of GARP2 in the outer
segment of rod photoreceptors. If GARP2 is present in sufficient amounts relative to
PDE6, then it is capable of regulating the entire pool of PDE6 during visual transduction.
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We also had to determine how GARP2 binds and regulates PDE6 catalytic activity, and
what are the consequences of GARP2 binding to PDE6 on the activation-inactivation
cycle of PDE6.
The second goal is to study the interaction of GARP2 with PDE6, and the effect
that GARP2 has on the PDE6 catalysis. In order to accurately determine GARP2
function, a method to obtain purified native GARP2 isolated from the photoreceptor cells
is required. One limitation of the Korschen et al study (1999) is the use of recombinant
GARP2 fusion protein, and the assumption that the tag does not influence the regulatory
properties of PDE6. In this thesis I describe several approaches for purifying native
GARP2 free of PDE6 subunits.
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CHAPTER 2

ISOLATION OF PDE6 INTERACTING PROTEIN COMPLEX
AND IDENTIFICATION OF ITS COMPONENTS. STRATEGIES
FOR PDE6 PURIFICATION.2

Abstract

Rod photoreceptor phosphodiesterase (PDE6) is the only phosphodiesterase that
is membrane associated through isoprenyl motifs at the C-terminal region of the catalytic
subunits. In order to study the PDE6 interactions with other proteins during the visual
transduction cascade, an effective solubilization method needed to be developed. We
found that 10 mM of the zwitterionic detergent CHAPS is able to solubilize the majority

2 Parts of this study were published in Methods in Molecular Biology: Pentia DC, Hosier
S, Collupy RA, Valeriani BA, Cote RH., 2005;307:125-40.
3 The abbreviations used are: PDE6, photoreceptor phosphodiesterase; Py, inhibitory 10
kDa y subunit of PDE6; GARP2, glutamic acid-rich protein 2; PrBP-8, 17 kDa prenylbinding protein; GST, glutathione S-transferase; GTPyS, guanosine 5’-3-0-(thio)triphosphate; ROS, rod outer segment; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl
fluoride; CHAPS, 3-(3-Cholamidopropyl)dimethylammonio)-l-propanesulfonate; BCA,
bicinchoninic acid.
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of PDE6 from the ROS membranes, and in the same time the ability of transducin to
activate solubilized PDE6 is not altered.
The second aim is to evaluate the light regulation of protein interactions with
PDE6. The different stages of light activation are induced by the use of nucleotides,
GTPyS for permanent activation of transducin, cGMP for the occupancy of the GAF
domains of PDE6, and ATP for protein phosphorylation. In the same time, various
solubilization methods are used for the analysis of the proteins that interact with PDE6.
We found that upon PrBP-5 solubilization, GARP2 is released from the PDE6 complex.
Also, PDE6 complex runs at higher than expected apparent molecular masses on size
exclusion chromatography, suggesting the presence of interacting proteins.
Based on the findings of PDE6 interacting proteins under different activation
conditions and the analysis of various solubilization methods, we developed an improved
method to purify PDE6 holoenzyme devoid of binding partners. A procedure to purify
PDEap heterodimer is also described.
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Introduction

Phosphodiesterase (PDE6) is the central effector in the phototransduction cascade
in rod and cone photoreceptors. The most abundant PDE6 isoform of rod photoreceptor
cells is the membrane-associated PDE6, present in the rod outer segment (ROS) portion
of the cell. Although displacement of the inhibitory y subunit of PDE6 (Py) by activated
transducin is the primary regulator of PDE6 activation, many other factors are thought to
be involved—directly or indirectly—in PDE6 regulation, including: Prenyl-binding
protein -6 (PrBP-8) (Cook et al., 2001; Mou et al., 1999; Norton et al., 2005), glutamic
acid-rich protein 2 (GARP2) (Korschen et al., 1999), regulator of G protein signaling 9
(RGS9) (He et al., 1998), and the GP5L isoform of G protein (Makino et al., 1999). We
sought to investigate potential protein-protein interactions between PDE6 and other
regulatory proteins, and how these interactions might be affected by light activation.
The study of proteins that interact with PDE6 during phototransduction is
hampered by the membrane-association of rod photoreceptor PDE6 on the disk
membrane. In addition, ROS membranes have been shown to be critical for efficient
activation of phototransduction (Malinski and Wensel, 1992; Melia et al., 2000).
Therefore, the optimal solubilization procedure for PDE6 that retained its activity but did
not disrupt disrupting protein-protein interactions has been researched. To do this, the
ability of various detergents, solubilizing proteins like PrBP-8, and hypotonic buffers to
release PDE6 from the membrane has been explored.
Because phototransduction is a dynamic process, regulated by the primary
messenger light, the interaction between its components is also dynamic. Proteins that
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take part in generating the electrical response are associating and dissociating depending
on the activation or deactivation state of the interacting partners. It is important therefore
to determine which proteins interact with each other during different phases of the visual
transduction cascade.
In order to determine the organization of the protein complexes in dark-adapted
and light-stimulated conditions, two variables have to be considered. First, the different
stages of visual activation have to be induced in the photoreceptor cells. Moreover, to
allow the separation of the protein complexes, the various steps of the activation process
have to be halted and preserved at least for the duration of the isolation procedure. The
second variable that has to be considered is the strength of interaction between proteins in
the complex. Some interactions are weak, and of short duration, such that different
procedures have to be used. Both of these considerations are addressed in the present
study.
In order to control the activation states of PDE6, the factors that regulate the
formation of each activation step need to be understood and controlled. PDE6 undergoes
different states of activation-inactivation during the phototransduction cycle that involve
primarily in the release and re-attachment of the inhibitory Py subunit (Hurley and Stryer,
1982). But the PDE6 holoenzyme can also be regulated by the binding of the cGMP to
the GAF domains (Yamazaki et al., 1982; Yamazaki et al., 1996; Cote et al., 1994; Mou
et al., 1999). This confers a means to regulate the activation state of PDE6 based on the
amount of cGMP present. Also the activation state of PDE6 is dependent on the
activation of transducin (Bennett and Clerc, 1989; Fung and Nash, 1983; Malinski and
Wensel, 1992; Otto-Bmc et al., 1993; Tyminski and O'Brien, 1984). Transducin gets
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activated by rhodopsin, and exchanges bound GDP for GTP. By controlling the
availability of GTP, it is possible to vary the extent of transducin activation. During de
activation however, GTP is hydrolyzed to GDP by the intrinsic GTPase activity of
transducin (Fung et al., 1981), such that activated transducin state is transient. To induce
persistent transducin activation, use of the non-hydrolyzable GTP analog GTPyS is
required. Some proteins involved in visual transduction (which directly or indirectly
influence PDE6 activation), are regulated by phosphorylation. One PDE6 subunit that is
thought to be phosphorylated under different activation states is Py (Hayashi, 1994;
Hayashi et al., 1991; Hayashi et al., 2000; Matsuura et al., 2000; Paglia et al., 2002;
Tsuboi et al., 1994a; Tsuboi et al., 1994b; Udovichenko et al., 1994; Xu et al., 1998).
There is also evidence that the catalytic dimer of PDE6 undergoes phosphorylation
(Udovichenko et al., 1993). Different states of those proteins could be controlled by the
addition of ATP as a substrate for protein kinases. Overall, the various stages of PDE6
activation-deactivation can be "frozen" by addition or omission of different nucleotides
that control various steps in the phototransduction pathway.
Another factor that needs to be considered when studying changes in protein
association during phototransduction is the ability to preserve protein interactions during
isolation of the protein complexes. Because some proteins are attached to the disk
membranes, and some interactions might be low affinity, the appropriate method needs to
be considered to extract the complex and preserve those interactions. In the present study
several solubilization methods are used, and compared with regard to the complex of
proteins that each method is isolating. Three methods have been used in this study:
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solubilization of the PDE6 protein complex using a hypotonic solution, using mild
detergent, or using the isoprenyl-binding protein PrBP-8.
In this study, we examine the PDE6 interacting proteins under different activation
states, using previously optimized methods of solubilization for PDE6 (Maftei, 2000).

Materials and Methods
1. Materials:
Bovine retinas were purchased from W. Lawson (Lincoln, NE). Chromatography
columns and media (Mono Q and Superdex prepacked columns, butyl-Sepharose, and QSepharose) were from GE-Healthcare, ceramic hydroxyapatite type I from Bio-Rad
Laboratories. Sulfolink coupling gel and Immunopure (G) IgG Purification Kit were from
Pierce. Membrane filtration devices were from Millipore. The ROS 1 monoclonal
antibody cell line was a kind gift from Dr. R. L.Hurwitz (Baylor College of Medicine).
Miscellaneous stock solutions were prepared as follows; 1 M DTT in water, 100
mM PMSF in 95% ethanol, mammalian protease inhibitor cocktail (P8340; Sigma
Chemical Corporation) as directed by manufacturer.
All solutions used to isolate and purify PDE6 are supplemented just before use
with 1 mM dithiothreitol (DTT) and 0.3 mM phenylmethylsulfonyl fluoride (PMSF) or
protease inhibitor cocktail (following the manufacturer’s recommendations). All
chromatography buffers were filtered with a 0.45-pm membrane under vacuum
immediately before use to remove particulates and degas the solvent.
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Antibodies: anti-noncatalytic domain of PDEap, from UNH; anti-transducin a, from
Affinity bioreagents; anti-C-terminal region of Py, from UNH; anti-GARP2, a kind gift of
Dr. Benjamin Kaupp (Julich, Germany).

2. Initial isolation ofPDE6 isoformsfrom bovine retina and purification o f ROS.
Mechanical disruption of photoreceptor cells from the neural retina was the
starting point for isolating both the rod photoreceptor PDE6 associated with the outer
segment membranes and the soluble rod and cone PDE6 that were recovered in the
soluble portion of the retinal extract. For the case of the membrane-associated PDE6,
sucrose density gradient centrifugation results in purified ROS in which rhodopsin (-70%
of total protein), transducin (-10% of total protein), and PDE6 (1 to 2% of total protein)
are membrane-bound. To prevent activation of the components of the phototransduction
pathway, the following procedures were performed in a darkroom with infrared (IR)
illumination and IR viewers. All solutions were ice-cold throughout the ROS purification
process.
50 frozen bovine retinas were quickly thawed and kept on ice once thawed. 45
mL of 45% (w/v) sucrose in solution A: (20 mM 3-morpholinopropane-l-sulfonic acid
(MOPS), pH 7.2; 2.0 mM MgCl2, 60 mM KC1; 30 mM NaCl supplemented with 200 pL
of Mammalian Protease Inhibitor Cocktail) was added to a beaker containing the 50
retinas. A magnetic stir bar was placed in the bottom of the beaker at low speed to
mechanically disrupt photoreceptors from the retinas for 1 h in the dark. The solution
containing the disrupted retinas was transferred to 50 mL centrifuge tubes and
centrifuged at 3000 x g for 3 min to pellet the retinal debris. The retinal extract

27

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

(containing ROS) was strained through a nylon sock into a cold beaker and was diluted
1.5-fold with solution A to dilute the sucrose concentration. The retinal extract was
centrifuged in 50 mL tubes for 30 min at 23,000 x g in a fixed angle rotor. The
supernatant was saved for purification of cone PDE6, and the pellet containing the ROS
was further purified.

3. Purification o f ROS.
The ROS-containing pellets were resuspended in 15 mL of solution B1 (51 mL of
50% sucrose in solution A are diluted to 100 mL with solution A; p = 1.105 g/mL). Just
before use, discontinuous sucrose gradients were prepared as follows in 18-mL centrifuge
tubes (Beckman) by layering 5 mL of solution B3 (64.5 mL of B1 diluted to 100 mL with
A; p = 1.135 g/mL), then 5 mL of solution B2 (54.25 mL of B1 diluted to 100 mL with
A; p = 1.115 g/mL). The resuspended ROS pellets (in solution B l) were layered within 1
cm of the top of the tubes. The sucrose gradients were centrifuged for 60 min at 116,000
x g in a swinging-bucket rotor at 4°C. The interface of solutions B2 and B3 containing
the purified ROS was removed with a 15-gauge needle attached to a 5-mL syringe. The
ROS was diluted with 2 vol. of solution A, and then centrifuged for 60 min at 30,000 x g
to pellet the purified ROS. ROS pellets were stored at -80°C until use.

4. Preparation o f ROS membranes containing PDE6.
The soluble proteins present in the ROS were removed by homogenizing (in a
Dounce tissue grinder at 4°C) the ROS in an isotonic buffer (10 mM Tris, pH 7.5, 60 mM
KC1,40 mM NaCl, 0.2 mM MgCU, 1 mM DTT) in the dark. ROS membranes were
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separated from the soluble proteins by centrifugation. The resulting ROS membranes
contain integral membrane proteins (predominantly rhodopsin), along with peripheral
membrane proteins (notably PDE6 and a reduced amount of transducin). Because
transducin undergoes a light-dependent binding to photoactivated rhodopsin (Kuhn,
1982), the ROS membranes were exposed to light just before releasing PDE6R with a
low ionic strength buffer (see next section).

5. Extraction o f PDE6 from ROS membranes with hypotonic buffer.
The ROS membrane pellets were exposed to room light for 1 min at 4°C to
photoactivate rhodopsin, thereby inducing tight binding of transducin to the ROS
membranes. The light-exposed ROS membranes were resuspended in a hypotonic PDE6
extraction buffer (10 mM Tris pH 7.5, 0.2 mM MgCb, 1 mM DTT). The ROS
membranes were homogenized in a Dounce tissue grinder at 4°C by 10 passes of the
pestle. The hypotonic extract was centrifuged for 60 min at 30,000 x g, and the hypotonic
supernatant, which contains solubilized PDE6 was recovered. The hypotonic extraction
procedure (without homogenization) was repeated two additional times. Pooled
hypotonic extracts were clarified by ultracentrifiigation at more than 100,000 x g for 30
min.

6. Purification o f PDE6 by Mono Q anion-exchange chromatography.
The hypotonic PDE6 solution was adjusted to the approximate ionic strength of
MQ-A buffer (10 mM Tris-HCl, pH 7.5,100 mM NaCl, 2 mM MgCl2) by adding 0.10
vol. of MQ-B buffer (MQ-A containing 1.0 M NaCl). The solution was filtered with a
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low-protein binding 0.22-pm filter to remove particulates. The PDE6 sample was loaded
onto the Mono Q column at a flow rate of 0.5 mL/min and the column was washed with 5
column vol. of MQ-A buffer. A linear salt gradient from 0% MQ-B (100 mM NaCl) to
100% B (1.0 M NaCl) in a total volume of 40 mL was performed, and 1-mL fractions
were collected. After the elution was completed, the Mono Q column was washed with 5
column vol. of MQ-B, and then stored as directed by the manufacturer. Fractions
containing PDE6 were identified by a colorimetric PDE activity assay (Cote, 2000).

7. Ultrafiltration o f PDE6 sample.
A centrifugal filter device (Centricon Plus-20; Millipore) with molecular weight cut-off
of 30 kDa was used to concentrate the PDE6 sample. The sample was loaded on top of
the filter, and spun in a centrifuge at 3500 x g. The concentrated sample was recovered
from the top of the filter, and the flow-through was discarded.

8. Gelfiltration chromatography o f PDE6.
The PDE6 sample volume was reduced by ultrafiltration to < 2% of the total
volume of the gel filtration column in order to obtain maximum resolution of the PDE6
peak. The gel filtration column was equilibrated with 2 column vol. of GFC buffer (10
mM Tris-HCl, pH 7.5,300 mM NaCl, 2 mM MgCL) prior to injecting the PDE6 sample
on the column. The column was operated at a flow rate of 0.4 mL/min and 0.3-mL
fractions were collected. The absorbance at 280 nm was monitored, and the PDE6
catalytic activity of each fraction was analyzed.
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9. Calibration o f the Superdex-200 gelfiltration column.
The following globular proteins were used to calibrate the Superdex-200 column:
aldolase (10 mg/ml), catalase (10 mg/ml), ferritin (1 mg/ml), thyrodlobuline (10 mg/ml),
and carbonic anhydrase (10 mg/ml). The void volume was measured with the use of
Blue-Dextran (1 mg/ml). 500 pL of each protein solution was injected individually, and
was eluted with GFC buffer. The OD28o was monitored throughout the run to detect the
protein peak.

10. Immunoprecipitation with ROS1 antibody.
The murine monoclonal antibody ROS1 was originally raised against the PDE6R
holoenzyme (Hurwitz et al., 1984). The epitope recognized by the ROS1 antibody has not
been defined, but the affinity of the antibody for PDE6R and PDE6C is very high
(Hurwitz et al., 1984).

10.1. Coupling o f ROS1 antibody to sulfolink beads.
ROS1 antibody was purified from ascites fluid on a Pierce Immunopure Protein G
agarose column using the manufacturer’s protocol. The eluted ROS1 antibody was
concentrated to less than 1 mL using a Centricon Plus-20, and diluted 10-fold with the
coupling buffer, and reconcentrated to >10 mg/mL in a volume of < 2.5 mL. ROS1
antibody was then coupled to the Sulfolink beads at a coupling density of 5 mg of
antibody/mL of resin following the manufacturer’s instructions.
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10.2. Purification ofPDE6 by adsorption to ROS1-Sulfolink column and elution o f active
enzyme.
ROS 1-Sulfolink column was washed with 10 column vol. of pH 10.8 elution
buffer (25 mM 3-cyclohexylaminopropane-1-sulfonic acid (CAPS), 200 mM NaCl, 2
mM MgCl2 , 10% glycerol, pH 10.8) at 1 mL/min, and then equilibrated with 10 column
vol. of TMN buffer (50 mM Tris-HCl, pH 7.5, 140 mM NaCl, 0.5 mM MgCl2). PDE6
sample was diluted in TMN buffer to adjust the pH and the ionic strength. PDE6 solution
was loaded onto the column at a flow rate of 0.5 mL/min.The eluate is recovered. The
beads were washed with 5 column volumes of TMN at 1 mL/min. Contaminating
proteins that nonspecifically bind to the ROS 1-Sulfolink beads were removed by washing
with 5 column vol. of pH 9.0 wash buffer (25 mM CAPS, 200 mM NaCl, 2 mM MgCl2,
pH 9.0). PDE6 was eluted with 10 column vol. of pH 10.8 elution buffer. 1-mL fractions
were collected in tubes containing 0.1 mL of neutralization buffer (1.0 M Tris-HCl, pH
6.7). The fractions are assessed for PDE activity using standard activity assays (Cote,
2000). Elution of active PDE6 from ROS1 has required extensive manipulation of buffer
conditions, with high pH and the inclusion of glycerol serving to elute the antibody with
the least loss of biological activity. Inclusion of a pH 9.0 wash step just prior to elution
served to eliminate proteins that would otherwise contaminate PDE6 preparation.
The ROS 1-Sulfolink resin is regenerated by washing with 5 column vol of pH
10.8 elution buffer, then 10 column vol. of TMN buffer containing 0.05% NaN3.
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11. Preparation o f PrBP-8.
E. coli cells containing the PrBP-8 plasmid (a kind gift of Drs. Terry Cook and
Joe Beavo; Univ. of Washington) were cultured overnight in a LB medium. 10 mL of the
overnight culture was inoculated in two flasks with 500 mL TY medium, and incubated
at 37°C until the OD600 reached 0.6-0.8. At this point, protein expression was induced
with 1 mM isopropyl-P-D-thiogalactopyranoside. The culture was incubated for another
hour at 37°C. Cells were pelleted by centrifugation, washed, and sonicated. The
supernatant containing the soluble proteins was separated from the cellular debris by
centrifugation. The extracted proteins were applied to a 2 mL glutathione-agarose
column. Bound GST-PrBP-5 was eluted with a solution contaning reduced glutathione,
and concentrated by ultrafiltration. The protein concentration of the purified GST-PrBP-8
was determined by a BCA protein assay (Smith et al., 1985).

12. Preparation o f PDEafi heterodimer.
To determining optimal conditions for trypsin activation of PDE6, it was
proteolyzed with trypsin at 4°C for various times to determine the minimum time
necessary to activate the enzyme fully. After quenching the reaction with a molar excess
of soybean trypsin inhibitor, samples were assayed for PDE6 catalytic activity.
PDE6 was diluted to a concentration o f200 nM in 2X proteolysis buffer (20 mM
Tris-HCl, pH 7.5, 200 mM NaCl, 4 mM MgCL, 40% glycerol), and an equal volume of
100 pg/mL of TPCK-treated trypsin in 10 mM Tris-HCl (pH 7.5) was added. At various
intervals, portions were removed and quenched with an equal volume of 2X proteolysis
stop solution (20 mM Tris-HCl, pH 7.5,200 mM NaCl, 4 mM MgCL, 0.5 mg/mL of
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soybean trypsin inhibitor, 0.4 mg/mL of bovine serum albumin, 0.4 mM Pefabloc, 4 mM
DTT). The quenched samples were assayed for catalytic activity using a colorimetric
PDE activity assay (Cote, 2000).
To prepare purified PDEaP dimer lacking Py or Py fragments, the trypsinactivated PDE6 was concentrated by ultrafiltration using a 30-kDa molecular mass cutoff
filter, and resuspended in MQ-A buffer. The PDE6 was reconcentrated to remove trypsin,
trypsin inhibitor, and some Py fragments from the PDE6 sample. Following this buffer
exchange procedure, the concentrated PDE6 sample was loaded onto a Mono Q column
as described above. The resulting fractions were analyzed for PDE6 activity, and
concentrated by ultrafiltration to a volume of less than 500 pL and stored at -20°C with
50% glycerol. An additional gel filtration step was occasionally used to further eliminate
residual Py fragments.
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Results and Discussion

1. Analyzing PDE6protein complexes by immunoprecipitation using various
solubilization methods.
Based on previous studies (Maftei, 2000), the solubilization methods that proved
to be the most effective in extracting PDE6 from the ROS membranes were either 10 mM
CHAPS, an excess of PrBP-8, or hypotonic extraction (using 5 mM Tris, pH 7.5,0.2 mM
MgCk). The zwiterionic detergent CHAPS is able to solubilize -90% of the total PDE6
in ROS membranes when used at 10 mM concentration (Maftei, 2000). The prenylbinding protein PrBP-8 can solubilize > 90% of the total PDE6 from the ROS membranes
when used in excess over PDE6 (30 PrBP-8 per PDE6) (Norton et al., 2005). PDE6 is
also released from the ROS membranes under hypotonic conditions, and -70% of the
total PDE6 can be extracted when using multiple hypotonic solubilizations (Kuhn, 1982).
PDE6 is in a dynamic equilibrium of association and dissociation with different
proteins involved in visual transduction. Various activation stages involve changes in
nucleotide binding and/or protein phosphorylation. Therefore, different PDE6 complexes
can be induced by the use of nucleotides in conjunction with illumination. The nucleotide
conditions used for inducing different activation states of PDE6 were: 1. Non-activated
ROS membranes washed of any endogenous nucleotides; 2. Persistently activated ROS
membranes supplemented with ImM GTPyS; 3. Activated ROS membranes with PDE6
GAF domains occupied by including 1 mM cGMP and ImM GTPyS; and 4. Activated
ROS membranes with occupied GAF domains, and proteins in their phosphorylated state,
by supplementing the ROS with 1 mM GTPyS, 1 mM cGMP and 1 mM ATP.
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Following nucleotide addition and solubilization of PDE6 from the ROS
membranes, the protein complex was isolated by immunoprecipitation using the antiPDE6 specific monoclonal antibody ROS1 (Hurwitz and Beavo, 1984) coupled to
agarose beads. The immunoprecipitated proteins are then separated on SDS-PAGE and
transferred to nitrocellulose membranes for immunodetection. The proteins probed for
were: PDEap, Py, GARP2 and transducin a (Ta).

CHAPS IPP
1 2 3
4

PrBP-8 IPP
1 2 3 4

Hypotonic IPP
1 2 3 4
PDEap

m-
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wE? ERp bB’
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Figure 2.1. Effect of transducin activation and nucleotide addition upon the
interaction of PDE6 with other peripheral membrane proteins.
ROS membranes (50 pM Rho) were treated with the following nucleotides: 1 - no
addition of nucleotides; 2 -1 0 0 pM GTPyS; 3 -1 0 0 pM GTPyS and 1 mM cGMP; 4 100 pM GTPyS, 1 mM cGMP and 1 mM ATP. The three extraction methods tested are:
detergent extraction using 10 mM CHAPS; PrBP-8 solubilization using 30 PrBP-8 per
PDE6; hypotonic extraction using a 5 mM Tris, 0.2 mM MgCb buffer. PDE6 extracts
were immunoprecipitated with 10 pL of 5 mg/ml antibody of ROS 1-Sulfolink beads. The
equivalent of 1 pmol of PDE6 was loaded in each lane. The antibodies used were: the
anti-catalytic PDE6 subunit, anti-full-length GARP2, anti-transducin a subunit, and antiC-terminus of the inhibitory Py subunit. The GARP2 band is a false positive, being the
heavy chain of the ROS1 antibody (see text below).

As seen in Fig.2.1., under all the conditions tested, Ta does not maintain an interaction
with PDE6. Because upon light activation Ta has a higher affinity for activated
rhodopsin on the ROS membrane, it is possible that all the solubilization methods used
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destroy the interaction between T a and PDE6, releasing only the PDE6. Another
possibility is that Ta competes with ROS1 antibody for the same binding sites on PDE6.
However, PDE6 is equally well immunoprecipitated in all cases. This finding would
suggest that the interaction between PDE6 and Ta is of low affinity, being disrupted
under the experimental conditions used.
Py has the strongest interaction with PDEaP under the nonactivated condition.
This is expected since PDE6 has a high affinity for Py in vitro. The absence of Py from
the activated PDE6 in the absence of the GAF domains occupancy (condition 2, CHAPS
extraction) correlates with the previously observed dissociation of Py from PDEaP upon
cGMP release from the GAF domains (Cote et al., 1994). The weaker signal for Py for all
hypotonic conditions could suggest the weakening of the Py affinity for PDE6 under the
hypotonic extraction conditions.
Initially we believed that GARP2 co-precipitated with PDE6 under all the
nucleotide conditions used. Closer examination revealed that the band that appears at 60
kDa (the molecular weight at which GARP2 runs) is actually the immunoglobulin (IgG)
heavy chain of the ROS1 antibody that dissociates from the beads upon treatment with
gel sample buffer. This heavy chain reacts with the horseradish peroxidase (HRP)conjugated secondary antibodies and appears as a band on the film. In order to detect
GARP2 in the PDE6 protein complex, we employed an alternative method using a biotinstreptavidin system to detect of the proteins of interest without antibody interference. All
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Figure 2.2. Proteins co-purifying with hypotonically extracted frog PDE6 on size
exclusion chromatography.
Hypotonically extracted frog PDE6 (500 pL of 200 nM PDE6) was chromatographed on
a Superdex-200 size exclusion column. A. 0.3 mL fractions were collected and analyzed
for PDE6 activity. B. 20 pL of each fraction in the PDE6 activity peak were further
analyzed on western blots, using anti-catalytic subunit PDE6, C-terminus Py, full-length
GARP2 and transducin a antibodies. One blot was probed sequentially for the catalytic
subunit of PDE6, Py and Ta, and another blot was probed for GARP2.

the antibodies used for protein detection were biotinylated, and proved to be effective in
detecting proteins of interest (data not shown). Studies were not carried to further to
analyze the PDE6 immunoprecipitating proteins using biotinylated antibodies.
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2. PDE6 interacting proteins solubilized by hypotonic extraction.
The inrmunoprecipitation method has several limitations, including the likelihood
of non-specific interactions with other proteins. An alternative method to isolate the
PDE6 interacting complex by size exclusion chromatography was therefore examined.
Size exclusion chromatography allows the separation of the protein complexes based on
the size of the complexes which will elute with different relative mobilities. Analyzing
the co-migrating proteins using western blotting, the identity of the proteins that form the
PDE6 complex can be determined. This method also has its limitations, particularly the
dilution induced dissociation of proteins that bind with low affinity which can occur
during size exclusion chromatography.
Extracting proteins from membranes, in this case from rod outer segments disk
membranes, was achieved by exposing the ROS membranes to a hypotonic solution. For
this purpose, frog ROS membranes were used. The advantage of frog ROS over bovine
ROS results from the ability to precisely control the light history of the ROS prior to
retinal isolation. ROS were purified in the dark, and subsequently exposed to light for the
different activation conditions during the hypotonic extraction process. The hypotonic
extract was subjected to size exclusion chromatography on a Superdex-200 column,
previously calibrated using globular proteins as standards (see Experimental Procedures).
Following size exclusion chromatography, the PDE6 peak was identified using a
colorimetric enzymatic assay (see Fig. 2.2). The apparent molecular weight of the
complex was determined to be ~600kDa, almost three times greater than the predicted
molecular weight of the PDE6 holoenzyme. Known interacting proteins (e.g. GARP2 (32
kDa), Ta (36 kDa)) may account in part for the larger than expected molecular weight of
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the complex. Other binding partners whose identity is unknown may also contribute to
the estimated molecular weight. Another factor that can contribute to the estimated
molecular weight of the complex is the shape of the PDE6 complex. For example, if the
protein complex has an ellipsoid shape, it will elute at apparent molecular weights greater
than if the complex was a globular shape. Western blot analysis of the proteins that co
elute with PDE6 after hypotonic extraction and size exclusion chromatography reveals
the presence of GARP2, the inhibitory Py subunit, and Ta.

3. PDE6 protein complex solubilized by detergent.
Previous work (Maftei, 2000) determined the optimal detergents and
concentrations for the release of PDE6 from the ROS disk membranes. For example, 10
mM CHAPS (a zwiterionic detergent) is able to release most of the PDE6 from the
membrane, while preseving transducin's ability to activate the solubilized PDE6.
However, detergent solubilization may also disrupt some protein-protein interactions.
A detergent extract of PDE6 was subjected to size exclusion chromatography.
Following the chromatographic run, the PDE6 peak was identified by PDE6 activity
assay. We found that PDE6 elutes in two separate peaks on the Superdex-200 column
(see Fig.2.3.). The first peak eluted in the void volume of the column. The second peak
eluted at an apparent molecular weight of ~380 kDa. This is also a greater molecular
weight than the calculated one. Analyzing proteins that elute in the second peak by
western analysis, it has been observed that GARP2 is absent, but PDE6 co-elutes with
PrBP-5 (data not shown). The binding of PrBP-8 to PDE6 could cause a more oblong
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shape of the complex, which could influence the relative mobility of the complex, and
result in a higher apparent molecular weight.
The most probable cause for the elution in the void volume is the formation of
micelles by the detergent. The critical micellar concentration of CHAPS is 5 mM, half the
concentration used to solubilize PDE6.
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Figure 2.3. Size exclusion chromatography profile of bovine PDE6 protein complex
solubilized using 10 mM CHAPS solution.
ROS membranes (200 pL of 100 pM Rho) were extracted with a solution containing 10
mM CHAPS. Following separation by size exclusion, fractions were analyzed for PDE6
activity. Two*peaks of PDE6 activity are found, the first one eluting in the void volume
of the column (Superdex 200), and assumed to be formed of detergent micelles, while the
second peak has an apparent molecular mass of ~380kDa. Western blot analysis shows
GARP2 and T a co-eluting in the first PDE6 activity peak, but GARP2 or T a not copurifying with PDE6 in the second PDE6 activity peak (data not shown).
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4. PDE6 protein complex released by binding to PrBP-S.
PrBP-8 is an isoprenyl binding protein whose function in photoreceptors is
unclear (Cook et al., 2001; Norton et al., 2005; Zhang et al., 2004). Nonetheless, because
PrBP-8 can completely solubilize PDE6 from membranes (Florio et al., 1996; Norton et
al., 2005), it can be used for studying PDE6 interacting complexes.
Purified recombinant bovine GST-PrBP-8 (30 PrBP-8 per PDE6) was used to
solubilize the entire pool of PDE6 from ROS disk membranes. This extract was analyzed
by size exclusion chromatography, and a single PDE6 activity peak was detected (see
Fig. 2.4.). Examining the protein elution peak (from the OD280) together with the PDE6
activity peak, it was determined that the apparent molecular weight of this peak was
around 400 kDa. Analysis of the proteins present in this peak reveals the absence of
GARP2. This result suggests that PrBP-8 dissociates GARP2 from PDE6 while it is
solubilizing PDE6 from the ROS membranes. The higher molecular weight of the
complex could be the result of the change in shape of the PDE6 complexed with PrBP-8.
It is not excluded that other proteins, not detected by us, also account for some or all of
the increase in molecular size of the PDE6 complex solubilized by PrBP-8.
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Figure 2.4. Size exclusion chromatography elution profile of PDE6 solubilized using
PrBP-5.
200 pL ROS of 100 pM [Rho] were treated with 30 PrBP-5 per PDE6 overnight. The
supernatant was separated from the membrane pellet, and subjected to size exclusion
chromatography. A. 300 pL fractions were collected and analyzed for PDE6 activity. One
single peak of PDE6 activity was found, and was calculated to elute at an apparent
molecular mass of -400 kDa (±100 kDa). B. 10 pL of the peak fractions were analyzed
on western blot with PDEaP and GARP2 antibodies.

Further studies have been conducted to determine the apparent molecular masses
of various preparations of PDE6 (see Table 2.1.).
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Sample

Apparent molecular mass

Soluble PDE6
(isotonically extracted)

410 ± 30, n = 2

Trysinized soluble PDE6

363 ± 47, n = 3

Membrane-attached PDE6
(hypotonically extracted)

420 ± 10, n = 2

Trypsinized membrane-attached PDE6

315±45, n = 4

PrBP-8 extracted PDE6

400, n = l

CHAPS extracted PDE6

380, n = 1 (second peak)

Table 2.1. Size exclusion chromatography analysis of various PDE6 species.
To determine whether PDE6 shape might account for the increased apparent
molecular weight, mildly trypsinized PDE6 was analyzed by size exclusion
chromatography. Upon mild trypsinization, both GARP2 and Py are destroyed. By
removing PDE6 associated proteins by trypsinization, we are able to obtain PDEaP
heterodimer free of other proteins. The apparent molecular mass of this protein was
calculated and compared to the molecular mass obtained from size exclusion
chromatography analysis. The apparent molecular weight decreases for both soluble
PDE6 and membrane attached PDE6. Hypotonically extracted PDE6 has an apparent
molecular mass slightly increased compared to detergent or PrBP-8 extracted PDE6. This
suggests that hypotonic extraction is the method that preserves most protein interactions,
while detergent and PrBP-8 disrupt some of those interactions.
Size exclusion chromatography cannot resolve the size of the protein complex
from the shape of the molecule. An oblong protein with a lower molecular mass will elute
at the same elution volume as a spherical protein with a higher molecular mass. In order
to definitively determine the composition of a protein complex, additional analysis by
SDS-PAGE followed by protein identification by mass spectrometry is necessary.
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5. Disrupting the PDE6 multi-protein complex by varying salt concentrations.
Some of the proteins that interact with PDE6 probably have a low affinity of
interaction which can be disrupted during the solubilization or purification process. PDE6
interacting proteins may come into contact with PDE6 only during certain steps of the
activation pathway. For example, we hypothesize in chapter 4 that GARP2 does not
interact with PDE6 throughout its activation cycle, but only at certain steps. Based on this
assumption, it may be possible to selectively separate PDE6 from GARP2 using different
solution conditions that disrupt their interaction. It has previously been shown that both
PDE6 and GARP2 are membrane bound, and PDE6 cannot be released by an isotonic
buffer solution (Kuhn, 1982). PDE6 remains membrane associated if ROS membranes
are exposed to a hypotonic solution supplemented with 20 mM MgCl2 (Kuhn, 1982).
Activated transducin separates from PDE6 if differential ionic strength of the extraction
buffer is used (Kuhn, 1982).
The experimental approach that we considered was to find a salt or MgCl2
concentration that would selectively disrupt the interaction between PDE6 and GARP2
and release one protein from the ROS membranes. The solutions used were 5 mM Tris,
pH. 7.5 and decreasing NaCl concentrations, from 150 mM to 10 mM. For the MgCl2
solution, a 5 mM Tris, pH 7.5 buffer was supplemented with MgCl2 concentrations
ranging from 20 mM to 1 mM. We observed that as the salt concentration was decreased,
PDE6 started to be released from ROS membranes at 25 mM NaCl, and was more than
90% solubilized at 10 mM NaCl (see Fig. 2.5.). GARP2 however, does not show a
distinct pattern of solubilization from PDE6, and also started to be released from ROS
membranes at 25 mM NaCl. For the MgCl2 concentration series, GARP2 began to be
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solubilized when MgCk concentration reaches 5 mM. Traces of GARP2 are also released
at 5 mM MgCk, but when MgC^ concentration is 2 mM, a large portion of PDE6, as
well as GARP2, are solubilized. Further work is needed in order to optimize the
separation conditions between PDE6 and GARP2. One approach is to induce various
activation states of PDE6 using nucleotides, and to test the above-mentioned buffer
compositions for each activation condition. The conclusion of this study is that under the
experimental conditions tested, PDE6 and GARP2 are associated with relatively high
affinity, and this affinity can not be differentially disrupted by the different ionic
conditions used.

5mM Tris, pH 7.5 with
decreasing salt concentrations (mM NaCl)

OO

5 mM Tris, pH 7.5 with
different Mg2+ concentrations (mM MgCI2)

o o

PDEaP
GARP2
Py
Supernatant

Pellet

Supernatant

Pellet

Figure 2.5. Attempts to selectively solubilize PDE6 from GARP2.
Bovine ROS membranes (100 pL of 50 pM Rho) were homogenized in the indicated
buffers and the soluble fraction separated from the membranes by centrifugation for 5
minutes at 130,000 x g in an Airfuge. 10 pL of each supernatant and of the resuspended
pellets were subjected to SDS-PAGE and western blotting. The blots were first probed
for GARP2 using a full-length anti-GARP2 antibody, and were probed next for PDEaP
and Py with anti- catalytic subunit and C-terminus Py antibodies.
r
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6. Purifying PDE6 from interacting proteins.
Based on the work described above, an improved purification scheme for PDE6 was
developed.

Retinal hom ogenate

crude ROS
Soluble retinal extract
(soluble PDE6R & PDE6C)

Density gradient centrifugation
Purified ROS (membraneassociated PDE6R)

Q-Sephamse chromatography

Hypotonic extraction
PDE6C

PDE6R

Mono

HIC

PDE6R

HAP

Gel filtration

ROS1- Sulfolink

Purified
PDE6R

PDE6C

Figure 2.6. Purification scheme for PDE6.
Abbreviations are: MonoQ, anion exchange chromatography on a GE-Healthcare MonoQ
column; HIC, hydrophobic interaction chromatography using butyl-Sepharose; HAP,
hydroxyapatite chromatography; ROS 1-Sulfolink, immunoafinity purification using
monoclonal PDE6 specific antibody ROS1 (see Materials and Methods).

The retinal homogenate is the source for both ROS membranes, with their
attached proteins, and soluble extract used for the purification of cone PDE6 and soluble
rod PDE6. The procedures described below address only the purification to homogeneity
of membrane-associated rod PDE6.
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For the purification of ROS membranes, a discontinuous sucrose density gradient
centrifugation step was required. Relying on the relative buoyancy of ROS, appropriate
concentrations of sucrose will separate ROS free of other retinal cells and debris
(McDowell, 1993); see Fig.2.6.). ROS obtained from 50 retinas contains 0.7-1 mg PDE6.
To extract PDE6 from ROS membranes, it is first necessary to remove the soluble
proteins present in the ROS. By disrupting the plasma membrane of the ROS in a
moderate ionic strength buffer in the dark, ROS membranes were separated from the
soluble proteins by centrifugation (Baehr et al., 1979). The resulting ROS membranes
contain integral membrane proteins (predominantly rhodopsin), along with peripheral
membrane proteins (notably PDE6 and a reduced amount of transducin). Because
transducin undergoes a light-dependent binding to photoactivated rhodopsin (Kuhn,
1982), the ROS membranes were exposed to light just before releasing PDE6 with a low
ionic strength buffer.
The next step in the purification of PDE6 is anion-exchange chromatography by
Mono Q. Anion-exchange chromatography of the PDE6 family has traditionally utilized
the weak anion exchanger, diethylaminoethyl (DEAE), as the functional group (Gillespie
and Beavo, 1988; Baehr et al., 1979). We find that greater reproducibility and better
resolution are achieved for PDE6 isozymes when a strong anion exchanger (quaternary
ammonium) is used. The purification of hypotonically extracted PDE6 on a Mono Q
column eliminates most other proteins, PDE6 purifying with a greater than 50% purity.
Membrane associated rod PDE6 elutes at -400 mM NaCl concentration, with transducin
subunits and GARP2 being the predominant impurity following this chromatographic
step (Fig. 2.7).
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Figure 2.7. Mono Q chromatography of hypotonically extracted PDE6.
Forty-five milliliters of hypotonically extracted PDE6R was loaded onto a Mono Q
column followed by 5 mL of MQ-A. PDE6R was eluted with a linear gradient from 0 to
100% MQ-B. For this particular experiment, the buffers were different from the standard
procedure: MQ-A lacked NaCl, and MQ-B was 800 mM NaCl. Absorbance (dotted line)
and conductivity (continuous line) were recorded, and PDE activity (—O—) was assayed
for each fraction collected.

Gel filtration chromatography is the most suitable final step for PDE6
purification. It not only purifies PDE6 from other proteins based on size, but it also
equilibrates the enzyme in a buffer more suitable for long-term storage (Fig. 2.8). The
relative purity of PDE6 after this step is greater than 50%, with the major contaminants
probably being proteolytic fragments of PDE6 and residual transducin subunits.
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Figure 2.8. Gel filtration chromatography of PDE6 on Superdex 200.
A 0.5-mL sample of Mono Q-purified PDE6 was injected onto a Superdex 200 HR 10/30
column at 0.4-mL/min, and 0.3-mL fractions were collected. The 280-nm peak at 7.5 mL
represents material in the void volume, with other impurities eluting at less than 100 kDa.
The protein and PDE activity peak at 11.0 mL has an apparent mol mass of 300 kDa.

As a final step in PDE6 preparation is concentration by ultrafiltration. Centrifugal
ultrafiltration serves three purposes: concentration of the PDE6 prior to storage, removal
of low molecular weight impurities, and exchange of the purification buffer with the PDE
storage buffer. In our experience, the Amicon/Millipore devices with the Ultracel PL
membrane (Centricon and Centricon Plus-20) offer the best rate of concentration and
highest recoveries for PDE6 isozymes.
The purity of PDE6 at different stages of purification is shown in Fig. 2.9.

50

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Rhodopsin
dimer

Rhodopsin

Figure 2.9. SDS-PAGE of membrane-associated PDE6 at various stages of
purification.
Samples were applied to 12% acrylamide gels and electrophoresed and the gel stained
with Coomassie Blue.
If ROS membranes contain about 1% PDE6 (Pugh, Jr. and Lamb, 1993), the
hypotonic extraction step greatly increases PDE6 purification. The major protein of ROS
membranes, rhodopsin (-70% of total protein), is not released by hypotonic extraction,
being a transmembrane protein. Other transmembrane proteins, such as peripherin, or
R9AP also are not released during the hypotonic extraction procedure. After hypotonic
extraction, the major contaminating protein is transducin. In intact ROS, transducin is ten
times more abundant than PDE6 (Pugh, Jr. and Lamb, 1993), and being a peripheral
membrane protein is solubilized along with PDE6 under hypotonic conditions.
The next steps in PDE6 purification greatly reduce transducin contamination, as
well as other proteins that co-solubilize with PDE6. After MonoQ chromatography, some
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proteins with the similar chromatographic properties co-purify with PDE6. After this
step, the sample contains -30% PDE6. Gel filtration chromatography eliminates most
proteins that are distinctly different in size from PDE6. In the end, the PDE6 sample is
purified, with greater than 50% purity. One contaminant in the PDE6 sample is likely to
be GARP2, which does not stain well with Coomassie Blue dye, therefore, it is difficult
to accurately assess the degree of contamination in the final PDE6 sample.

7. Purifying the PDE6 catalytic dimer.
Because of the very high affinity with which Py binds to the catalytic dimer of
PDE6 (Wensel and Stryer, 1988), the most effective way to prepare PDEaP is to digest
the Py subunits by limited proteolysis. Under controlled conditions, trypsin can
effectively degrade the Py-subunits (and relieve their inhibition of the active site) without
affecting the properties of the catalytic dimer of PDE6 (Hurley and Stryer, 1982; Catty
andDeterre, 1991; Mou et al., 1999).
Although limited proteolysis with trypsin effectively activates PDE6 without
adversely affecting the catalytic subunits, a large proteolytic fragment of Py consisting of
the C-terminal half of the protein is generated (Fig. 2.10). This peptide has low affinity
for binding to the active site of the enzyme (Artemyev and Hamm, 1992; Mou and Cote,
2001), but at high concentrations Py C-terminal peptides can act as competitive inhibitors
of catalysis (Mou and Cote, 2001). MonoQ chromatography successfully removes the 5
kDa contaminating Py peptide from the PDEap dimer (see Fig. 2.10., last lane). For a
complete removal of traces of the peptide, a gel filtration purification of the PDEap
dimer is necessary.
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Following this procedure for purifying PDEaP (see Materials and Methods), a Pyffee heterodimer sample is obtained, allowing an accurate study of the catalytic and
regulatory properties of the catalytic dimer, and of the proteins that might interact with it.
The time course of disappearance of the 11-kDa Py-subunit correlates with the
appearance of an approx 5 kDa Py fragment (amino acids 45-87). The aand P
catalytic subunits are not degraded by this treatment. Following purification of the
trypsin-activated PDE6 on Mono Q (MQ-tPDE), most of the Py fragment is removed.

Trypsinization time (min)

0 0.5 1 2 3 5 10 15 20 30 40 50
P a /p Py full-length Py fragment -

Figure 2.10. Proteolytic digestion of PDE6 holoenzyme preferentially destroys the
Py-subunit
PDE6 (50 nM) purified by Mono Q and gel filtration chromatography was incubated with
50 jig/mL of trypsin at 4°C. At the indicated times, samples were mixed with soybean
trypsin inhibitor and run on SDS-PAGE. After transfer to a nitrocellulose membrane at
60 V for 1 h, the membrane was probed with a mixture of catalytic and inhibitory subunit
antibodies.

Summary
This study analyzed proteins interacting with PDE6 during different stages of
PDE6 purification or phototransduction activation. The various nucleotide conditions for
activation of PDE6 were used to evaluate whether different proteins associate with PDE6
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in an activation-dependent manner. It appeared that T a is not co-solubilizing with PDE6
under light activation conditions, co-precipitating with PDE6 only for the dark-extracted
sample. In the absence of an effective solubilization method that would not interfere with
the affinities of the interacting proteins, different methods were assessed in their ability to
solubilize and preserve protein interactions. The interacting proteins were evaluated in
their relative affinities for PDE6 during the visual cycle. Also, the method chosen for
isolation of the PDE6 protein complex may interfere with some protein-protein
interactions, and can result in false positives for proteins of the same molecular weight as
heavy or light chain of the immunoprecipitating antibody (e.g. GARP2). It is needed to
further explore other methods for isolating the PDE6 protein complex, and for
identification of the interacting proteins, such as the use of biotinylated antibodies to
reduce heavy and light chain interference, analytical ultracentrifugation to determine the
size and shape of the protein complex, and SDS-PAGE followed by mass spectrometry
for identification of the unknown proteins. Based on the analysis of the efficiency of the
solubilization methods used and on their ability to preserve or destroy protein
interactions, a purification method for PDE6 was developed.
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CHAPTER 3

THE GLUTAMIC ACID-RICH PROTEIN-2 (GARP2) IS A HIGHAFFINITY ROD PHOTORECEPTOR PHOSPHODIESTERASE
(PDE6) BINDING PROTEIN THAT MODULATES ITS CATALYTIC
PROPERTIES4

Abstract
The glutamic acid-rich protein-2 (GARP2)5 is a splice variant of the P-subunit of
the cGMP-gated ion channel of rod photoreceptors. GARP2 is believed to interact with
several membrane-associated phototransduction proteins in rod photoreceptors. In this
paper, we first demonstrate that GARP2 is a high-affinity PDE6 binding protein, and that
PDE6 co-purifies with GARP2 during several stages of chromatographic purification. We
find that hydrophobic interaction chromatography succeeds in quantitatively separating

4This paper was published in the Journal of Biological Chemistry: Pentia, D.C., Hosier,
S., Cote, R.H. 2006 Mar 3;281(9):5500-5
s The abbreviations used are: GARP2, glutamic acid-rich protein 2; PDE6, photoreceptor
phosphodiesterase; Py, inhibitory 10 kDa y subunit of PDE6; PrBP/8,17 kDa prenylbinding protein; GST, glutathione S-transferase; GTPyS, guanosine 5’-3-0-(thio)triphosphate; ROS, rod outer segment; DTT, dithiothreitol; PMSF, phenylmethylsulfonyl
fluoride; HIC, hydrophobic interaction chromatography.
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GARP2 from the PDE6 holoenzyme. Furthermore, the 17 kDa prenyl binding protein
abundant in retinal cells selectively releases PDE6—but not GARP2—from rod outer
segment membranes, demonstrating the specificity of the interaction between GARP2
and PDE6. Purified GARP2 is able to suppress 80% of the basal activity of the non
activated, membrane-bound PDE6 holoenzyme at concentrations equivalent to its
endogenous concentration in rod outer segment membranes. However, GARP2 is unable
to reverse transducin activation of PDE6 (in contrast to a previous study), nor does it
significantly alter catalysis of the fully activated PDE6 catalytic dimer. The high binding
affinity of GARP2 for PDE6 and its ability to regulate PDE6 activity in its dark-adapted
state suggest a novel role for GARP2 as a regulator of spontaneous activation of rod
PDE6, thereby serving to lower rod photoreceptor “dark noise” and allowing these
sensory cells to operate at the single photon detection limit.
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Introduction

The visual transduction pathway in vertebrate photoreceptors is remarkable in many
respects, including single photon detection capability (in rod photoreceptors),
photoresponse kinetics on the millisecond time scale, and the ability to adapt to
background illumination levels ranging from very dim illuminance levels (scotopic vision
in rods) to bright sunlight (photopic vision in cones) (Rodieck, 1998). The very first steps
in vision occur in the photoreceptor outer segment when photoisomerized rhodopsin
activates the heterotrimeric G-protein, transducin, which proceeds to bind to and displace
the inhibitory y subunit (Py) of the photoreceptor phosphodiesterase (PDE6). Activated
PDE6 rapidly lowers the cGMP concentration, resulting in closure of cGMP-gated
channels in the plasma membrane and cell hyperpolarization (Bums and Baylor, 2001;
Arshavsky et al., 2002; Zhang and Cote, 2005). Several feedback mechanisms operate to
actively terminate the photoresponse and restore the dark-adapted state, of which
regulation of the lifetime of activated transducin is considered rate-limiting (Arshavsky et
al., 2002; Bums and Baylor, 2001). Re-binding of Py to the PDE6 catalytic subunits
following transducin deactivation returns PDE6 to its nonactivated state and allows
cGMP levels to return to their dark-adapted levels.
Electrophysiological evidence supports the hypothesis that factors in addition to
transducin deactivation are involved in regulating the lifetime of light-activated PDE6
during light adaptation of rod photoreceptors (Calvert et al., 2002; Krispel et al., 2003).
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Several potential feedback mechanisms for modulating activated PDE6 have been
proposed (Erickson et al., 1992; Korschen et al., 1999; Hayashi et al., 2000), but have not
been explored in sufficient detail to validate their relevance to the phototransduction
pathway.
The catalytic activity of PDE6 in its dark-adapted state also must be tightly
controlled to prevent spontaneous activation of PDE6 that would consume metabolic
energy unnecessarily and impair the ability of rod cells to reliably detect very dim flashes
of light. Physiological measurements of “dark noise” reveal a component that represents
spontaneous activation of PDE6, and which is much greater in magnitude in cones than in
rods (Rieke and Baylor, 1996; Rieke and Baylor, 2000; Holcman and Korenbrot, 2005).
Subtle differences in the highly homologous rod and cone isoforms of PDE6 might
account for the different “dark noise” in rods and cones, although this is not evident from
biochemical comparisons of purified rod and cone PDE6 (Baehr et al., 1979; Gillespie
and Beavo, 1988; Mou et al., 1999; Huang et al., 2004). An alternative possibility is that
a rod- or cone-specific PDE6 binding protein suppresses the spontaneous activation of
PDE6 by enhancing the affinity of Py at the PDE6 catalytic site.
One candidate protein that might serve to regulate PDE6 in both its nonactivated and
activated states is the glutamic acid-rich protein-2 (GARP2), a protein that exists in rod
outer segments but is absent in cones (Colville and Molday, 1996; Korschen et al., 1999).
GARP2 is a product of alternative splicing of the P-subunit of the rod cGMP-gated ion
channel (CNGB1) and contains a unique 8-amino acid C-terminal extension (Colville and
Molday, 1996; Korschen et al., 1999). This 32 kDa protein is unusual in that it has a high
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content of proline and glutamate residues (Sugimoto et al., 1991; Colville and Molday,
1996; Korschen et al., 1995).
The functions served by GARP2 in rod outer segments are unknown. Potential
binding partners for GARP2 include proteins involved in phototransduction and disk
membrane structural integrity (Korschen et al., 1999; Poetsch et al., 2001) but the
physiological significance of these interactions is unclear. In one previous study, it was
reported that addition of GARP2 to preparations of PDE6 reversed its activation by
transducin, whereas GARP2 had no effect on the nonactivated PDE6 holoenzyme or on
the catalytic dimer of PDE6 lacking bound Py (Korschen et al., 1999). It was proposed
that GARP2 down-regulation of PDE6 activation in the vicinity of the plasma membrane
might conserve metabolic energy during daylight when rod function is saturated.
In this paper we examine the interaction of GARP2 with PDE6, and characterize the
effect of GARP2 on PDE6 function. We show that GARP2 binds PDE6 with high
affinity, and co-purifies with the enzyme through several stages of purification. We have
been unable to confirm the previously reported inhibitory effect of GARP2 on transducinactivated PDE6 (Korschen et al., 1999). Instead, we observe that purified, native GARP2
has a strong effect in suppressing the basal activity of PDE6 in its nonactivated state. The
implications of GARP2 modulation of basal PDE6 activity in dark-adapted rods are
discussed.
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Materials and Methods

Materials—Bovine retinas were purchased from W. L. Lawson, Inc.
Chromatography supplies were purchased from GE Healthcare and Pierce. Supplies for
immunoblotting were purchased from Schleicher & Schuell, Pierce, and Bio-Rad.
Chemicals were obtained from Sigma. The bovine recombinant GST-PrBP/8 fusion
protein was a kind gift of Dr. Joe Beavo (Univ. of Washington). Rabbit polyclonal antiGARP2 antibody to the unique C-terminal sequence of GARP2 (Colville and Molday,
1996) was obtained from Affinity Bioreagents (catalog #PAl-728). Chicken and rabbit
polyclonal anti-GARP antibodies to bovine sequences common to GARP1, GARP2, and
the rod P-subunit CNGB1 were kind gifts of Dr. Steven Pittler (Univ. Alabama) and Dr.
Benjamin Kaupp (Inst. Biol. Inform., Jiilich). Affinity-purified anti-peptide rabbit
polyclonal antibodies directed to the PDE6 GAFb domain (termed NC) and to the Cterminus of the Py subunit of PDE6 (CT-9710) were produced in our laboratory. The
ROS1 monoclonal antibody used for immunoprecipitations (Hurwitz et al., 1984) was a
gift of Dr. Richard Hurwitz (Baylor College of Medicine).
ROS membrane isolation and purification—ROS membranes from bovine retina
were prepared as described previously (Pentia et al., 2005). Briefly, ROS were isolated
from frozen bovine retinas on a discontinuous sucrose gradient. ROS membranes were
homogenized in an isotonic buffer (10 mM Tris, pH 7.5, 60 mM KC1,40 mM NaCl, 2
mM MgCl2 , 1 mM DTT, 0.3 mM PMSF) using a glass, handheld homogenizer. The
soluble proteins were separated from membranes by centrifugation.
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Native GARP2 purification—GARP2 was isolated from ROS membranes and
purified to homogeneity as follows. First, ROS membranes were homogenized in a
hypotonic buffer (5 mM Tris, pH 7.5, 0.2 mM MgC^, 1 mM DTT). The soluble proteins
were separated from membranes by centrifugation at 100,000 g for 45 min. The
hypotonic extraction was repeated three times. The pooled hypotonic extract was then
adjusted to 500 mM ammonium sulfate and applied to a 15 ml Butyl-Sepharose column.
The column was washed of unbound proteins using two column volumes of 500 mM
ammonium sulfate in 5 mM Tris, pH 7.5, and bound proteins were eluted by a step
gradient: 400 mM ammonium sulfate, 150 mM ammonium sulfate, and no ammonium
sulfate in a solution containing 5 mM Tris, pH 7.5,1 mM DTT. The GARP2-containing
fractions were pooled, adjusted to 500 mM ammonium sulfate, and re-chromatographed
on Butyl-Sepharose. To concentrate and further purify GARP2 from other contaminating
proteins, anion exchange chromatography on Mono Q was used exactly as described for
PDE6 purification.
In some instances, the GARP2-containing fractions from the first Butyl-Sepharose
column were chromatographed on a Mono Q column prior to a final purification using a
reversed phase HPLC column (Vydac 214TP54) with a gradient of 0 to 100% acetonitrile
containing 0.1% trifluoroacetic acid. Under these conditions, GARP2 eluted at 48%
acetonitrile, Py was found at 43% acetonitrile, and PDE6 catalytic subunits were
undetectable by immunoblot analysis. HPLC-purified GARP2 behaved identically to
Butyl-Sepharose purified GARP2 in its effects on PDE6 catalysis.
PDE6 purification—Purified PDE6 was prepared as described elsewhere (Pentia et
al., 2005). Briefly, a hypotonic extract of purified ROS membranes was loaded onto a
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MonoQ column. The proteins were eluted using a linear gradient from 100 mM NaCl to 1
M NaCl in 5 mM Tris, pH 7.5. The PDE6 peak was collected, concentrated, and further
purified on a Superdex 200 gel filtration column using the following buffer: 5 mM Tris,
pH 7.5, 300 mM NaCl, 1 mM DTT and 3 mM PMSF. The gel filtration column was
calibrated using the following: thyroglobulin (669 kDa), ferritin (440 kDa), catalase (232
kDa), aldolase (158 kDa), bovine serum albumin (43 kDa), ovalbumin (29 kDa), Blue
Dextran for the void volume and adenosine triphosphate for the included volume.
Immunoprecipitation ofPDE6 with the monoclonal antibody ROS1—The ROS1
antibody to PDE6 (Hurwitz et al., 1984) coupled to Sulfolink beads (Pierce) was used for
immunoprecipitation of PDE6 and its binding partners. Hypotonic extracts from bovine
ROS or MonoQ-purified PDE6 (containing 5 to 10 pmol of PDE6) were incubated for 2
hours at 4°C with 20 pi pre-washed ROS1 beads in a total volume of 100 pi. Samples
were centrifuged to separate bound from unbound proteins, and beads were washed
extensively before proteins were eluted in Laemmli sample buffer. As a control for non
specific binding of GARP2 to the beads, purified GARP2 was also tested with the ROS1Sulfolink beads. Portions of the starting material, bound proteins and unbound proteins
were subjected to SDS-PAGE, followed by Western blotting for PDE6 (NC antibody)
and GARP (chicken anti-GARP antibody).
PrBP/S expression and purification—Recombinant bovine PrBP/S was expressed in
the Escherichia coli strain BL21 (Norton et al., 2005). Protein expression was induced by
addition of 1 mM isopropyl-P-D-thiogalactopyranoside to log phase cultures. Bacterial
cells were incubated for lh at 37°C, lysed by sonication, and soluble proteins were
recovered following centrifugation. GST-PrBP/8 was purified on a glutathione-agarose
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column. GST-PrBP/5 concentration was determined by a colorimetric protein assay
(Smith et al., 1985).
Protein quantification—The amount of rhodopsin in dark-adapted ROS membranes
was determined by difference spectroscopy (Bownds et al., 1971). The PDE6
concentration was routinely determined by measurements of trypsin-activated PDE6
maximum activity [VmaxJ (Cote, 2000)] and knowledge of the turnover number (kcat =
5600 cGMP/s/PDE6; ref. (Mou and Cote, 2001)]: [PDE6] = Vmax/kcat- Independent
determinations of the ratio of rhodopsin to PDE6 in purified bovine ROS gave a value of
310 ± 20 rhodopsins per PDE6 (n = 5), very similar to the values for amphibian ROS of
270 (Dumke et al., 1994) to 330 (Cote and Brunnock, 1993) rhodopsins per PDE.
The amount of purified GARP2 was routinely estimated by immunoblot analysis.
Samples of purified GARP2 and known amounts of ROS membranes were resolved on
SDS-PAGE and immunoblotted. GARP2 was detected using a GARP2-specific antibody.
The intensities of GARP2 immunoreactive bands were determined using Quantiscan
(Biosoft), and compared to GARP2 immunoreactivity in ROS membranes containing
known amounts of rhodopsin and PDE6.
SDS-PAGE and Western blotting—SDS-PAGE was performed by the method of
Laemmli (Laemmli, 1970) in 10%, 12% or 15% acrylamide gels. The immunoblotting
procedure followed the protocols in Gallagher (Gallagher, 1998). Note that GARP2
typically migrates at ~60 kDa (roughly 2-fold higher than predicted based on its amino
acid sequence) and shows size heterogeneity, in accord with previous observations
(Korschen et al., 1995; Korschen et al., 1999). This anomalous behavior was recently
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explained as being due to GARP2 existing in solution as a natively unfolded protein
(Batra-Safferling et al., 2006).

Results and Discussion
GARP2 is a high-affinity PDE6 binding protein—Because there is uncertainty about
the proteins with which GARP2 interacts in rod photoreceptors (Korschen et al., 1999;
Poetsch et al., 2001), we first re-examined whether PDE6 interacts in a specific manner
with GARP2. Following homogenization of purified ROS from bovine retina and
removal of soluble proteins with isotonic washes, PDE6 and GARP2 both remain
associated with ROS disk membranes (Fig. 3.1. A). Release of PDE6 from ROS
membranes by exposure to a hypotonic buffer also causes the release of almost all
detectible GARP2 (Fig. 3.1. A). Subsequent purification of PDE6 by anion-exchange
chromatography on a MonoQ column results in co-elution of PDE6 and GARP2 at 400
mM NaCl. Gel filtration chromatography of the Mono Q-purified GARP2-PDE6 also
failed to separate GARP2 from PDE6 (Fig. 3.1. A). The results in Fig. 3.1. A
conclusively demonstrate that PDE6 and GARP2 are both associated with ROS
membranes, are co-eluted by exposure to a hypotonic buffer, and co-purify by two
different chromatographic procedures.
To directly show that GARP2 is associated with PDE6, we immunoprecipitated
PDE6 with the ROS1 antibody (Hurwitz et al., 1984) coupled to Sulfolink beads. Fig. IB
shows that unpurified PDE6 obtained from hypotonic extraction of ROS membranes is
pulled down in a complex with GARP2, and that very little GARP2 remains unbound
under these conditions. MonoQ-purified PDE6 is also immunoprecipitated in tight
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association with GARP2, whereas purified GARP2 fails to bind to the ROS1 antibody in
the absence of PDE6 (Fig. 3.1. B).
To estimate whether a significant amount of the PDE6 exists free of bound GARP2,
we performed gel filtration chromatography on proteins solubilized from dark-adapted
ROS membranes with a hypotonic buffer. A single peak of PDE6 hydrolytic activity (Fig.
3.2. A) and immunoreactivity (Fig. 3.2. B) was observed at an apparent molecular weight
of 330 kDa. [The higher than predicted molecular weight for the PDE6-GARP2 complex
by gel filtration chromatography may be due to its asymmetric shape (Gillespie and
Beavo, 1988).] Qualitatively, the observed ratio of PDE6 and GARP2 immunoreactivity
did not vary in the fractions containing PDE6, indicating that there is not a large fraction
of the total PDE6 that exists free of bound GARP2. Further, only small amounts of
GARP2 immunoreactivity could be detected at an apparent molecular weight of -30-60
kDa (Fig. 3.2. B). This result indicates that PDE6 is tightly associated with GARP2 and
that there is no evidence for a significant amount of unbound GARP2 or PDE6.
To assess whether GARP2 binding to PDE6 might be an artifact of the initial
hypotonic extraction of ROS membrane proteins, we also solubilized PDE6 and GARP2
from dark-adapted ROS membranes with 1% Triton X-100. After removing the ROS
membranes by centrifugation and immunoprecipitation of the detergent-solubilized PDE6
with the ROS 1 antibody, we detected both PDE6 and GARP2 in the immunoprecipitates;
control samples with beads lacking the ROS1 antibody failed to pull down either protein
(data not shown).
Together, these results demonstrate that most of the GARP2 in ROS co-purifies with
PDE6 through several stages of purification. The fact that GARP2 remains bound to

65

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

PDE6 after repeated washing of the ROS1 immune complex (Fig. 3.1. B) and that little
unbound GARP2 is observed during gel filtration chromatography (Fig. 3.2.)
demonstrates that GARP2 binds PDE6 with high affinity.

A.

ROS IS

HS HM MQ GF

GARP2

I
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B U

MQ
I B U

GARP2
IB

GARP2

Figure 3.1. GARP2 is a high affinity PDE6 binding protein. A: Immunoblot of
PDE6 samples during purification. Purified ROS membranes (ROS), hypotonic extract
of ROS membranes (HS), MonoQ purified PDE6 (MQ) and gel filtration purified PDE6
(GF) lanes were each loaded with 1 pmol of PDE6. For the isotonic supernatant (IS), a
volume equivalent to the original ROS homogenate was loaded; for the ROS membranes
following hypotonic extraction (HM), an amount of rhodopsin equivalent to the ROS
sample was loaded. The blots were probed with the PDE6 NC antibody and the GARP2specific antibody.
B. Co-immunoprecipitation of PDE6 with GARP2. Hypotonically extracted PDE6
(Hypo.), MonoQ-purified PDE6 (MQ) or purified GARP2 were incubated with ROS1
antibody attached to Sulfolink beads (see Experimental Procedures). Samples
representing 10% of the total PDE6 sample (input, I), 50% of bound proteins (B), and
10% of the unbound proteins (U) were run on 15% SDS-PAGE, and immunoblots were
examined with antibodies specific for PDE6 and GARP. As a control for non-specific
binding of GARP2 to the beads, immunoprecipitation was also carried out on PDE6-ffee
purified GARP2, and samples representing 10% of the input and 50% of the pellet were
analyzed, (this result was obtained by Suzanne Hosier)
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Figure 3.2. GARP2 and PDE6 co-elute upon size exclusion chromatography. A: A
hypotonic extract of ROS membrane proteins (200 nM PDE) was loaded on a Superdex
200 column. The protein absorbance profile (continuous line) and the PDE6 activity
(filled circles) are shown. The top x-axis shows the molecular mass of protein standards
run on the column. Numbers adjacent to data points refer to fractions used for
immunoblot analysis.
B. Immunoblots of a fixed volume of the indicated column fractions were probed with
PDE6 and GARP2-specific antibodies.
GARP2 content in rod photoreceptors—If GARP2 is to regulate PDE6 activity
during phototransduction, it would need to be present in ROS in molar equivalence to
PDE6. A previous study by Kaupp and colleagues has suggested that GARP2 is actually
~3-fold more abundant than PDE6 [1 GARP2 per 100 rhodopsins (Korschen et al.,
1999)]. Another GARP2 interacting protein, peripherin, is believed to bind only 10% of
the total GARP2 in ROS (Poetsch et al., 2001). Our observation that practically all
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GARP2 in bovine ROS co-purifies with PDE6 (Fig. 3.1. and Fig. 3.2.) suggests that
GARP2 is not significantly more abundant than PDE6 in ROS.
To directly address the question of the GARP2 content in ROS, we purified native
GARP2 from bovine ROS as described below, and compared the immunoreactivity of
known amounts of GARP2 to that of intact ROS whose rhodopsin and PDE6
concentration were measured. The precision of our measurements were hampered by
uncertainties in the concentration of purified GARP2 used for quantitative immunoblots,
because the poor staining of GARP2 by Coomassie and other protein stains limited our
ability to assess its purity on SDS-PAGE (see next section). Taking this into
consideration, we estimate that there are 1-2 GARP2 molecules per PDE6 holoenzyme in
bovine ROS (data not shown). This value agrees well with two other reports (Korschen et
al., 1999; Batra-Safferling et al., 2006), and indicates that GARP2 is present in rod
photoreceptors in sufficient amounts to bind all of the PDE6.
Purification o f native GARP2,free o f contamination with PDE6—In order to study
the effects of GARP2 on PDE6 catalytic activity, we needed to purify GARP2 free of
PDE6 subunits. We discovered that the association of GARP2 with PDE6 could be
dismpted using high concentrations of ammonium sulfate. This permitted separation of
the two proteins by hydrophobic interaction chromatography (HIC).
A hypotonic extract containing PDE6 and GARP2 was mixed with 500 mM
ammonium sulfate, and the sample was applied to a Butyl-Sepharose column. A
decreasing, discontinuous ammonium sulfate gradient permitted the separation of PDE6
(at higher ammonium sulfate concentrations) from the GARP2 (which eluted only when
ammonium sulfate was omitted from the buffer (Fig. 3.3. A). Examination of the PDE6
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peak by immunoblot analysis revealed no detectible GARP2 (Fig. 3.3. B, “HIC-PDE”).
The disruption of GARP2 binding to PDE6 by ammonium sulfate suggests that
hydrophobic domains in GARP2 (which contains 27% hydrophobic amino acids) may be
important in promoting its binding to PDE6 catalytic subunits.
The GARP2 peak eluting from the Butyl-Sepharose column in the absence of
ammonium sulfate still contained traces of the inhibitory Py subunit immunoreactivity at
-12 kDa, as well as a faint band of GARP1 immunoreactivity at -130 kDa (Fig. 3.3. B,
“HIC1”). By exposing the partially purified GARP2 sample to 500 mM ammonium
sulfate and running the sample on Butyl Sepharose again, most of the residual Py was
removed from the GARP2 (Fig. 3.3. B, “HIC2”). Alternatively, the GARP2-enriched
fractions from the Butyl-Sepharose could be completely separated from PDE6 subunits
by reversed phase HPLC.
On Coomassie-stained gels of purified GARP2, greater than 50% of the total staining
is observed at -60 kDa, corresponding to GARP2 (Fig. 3.3. C). No detectable protein is
observed at molecular weights corresponding to PDE6 catalytic or inhibitory subunits.
The GARP2 purity is likely to be much higher, since this glutamate-rich protein binds
Coomassie protein stain very poorly relative to other proteins. It is therefore unlikely that
the effects of GARP2 on PDE6 activity reported below can be ascribed to a
contaminating protein in our purified GARP2.
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Figure 3.3. Separation of GARP2 from PDE6 by Butyl Sepharose chromatography.
A: A hypotonic extract (containing 2.2 nmol PDE6) was adjusted to 500 mM ammonium
sulfate concentration before being loaded on a 15 ml Butyl-Sepharose column. The
ammonium sulfate concentration was lowered in steps as indicated at the top of the
graph, and verified by conductivity measurements. The protein absorbance (continuous
line) and PDE6 activity profile (filled circles) were determined. B: Immunoblots
showing the starting material (ROS membranes; 0.5 pmol PDE), the PDE6 peak from
Butyl-Sepharose chromatography (0.5 pmol PDE6), and equivalent volumes of GARP2
following one or two purifications of the GARP2 peak eluting at zero ammonium sulfate
concentration. Immunoblots were probed with the rabbit anti-GARP antibody (upper
panels), and the anti-Py subunit antibody (CT-9710; lower panels). C: HPLC-purified
GARP2 (5 pg protein) was loaded on a 10% polyacrylamide gel, and the separated
proteins stained with Coomassie dye. The position and size (in kDa) of protein standards
are indicated.

The 17 kDa prenyl binding protein (PrBP/S) releases PDE6, but not GARP2,from
ROS membranes— The 17 kDa prenyl-binding protein (PrBP/8)—originally described as
the 8 subunit of PDE6 (Gillespie et al., 1989)—is able to solubilize membrane-associated
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rod PDE6 in vitro (Florio et al., 1996; Norton et al., 2005) by binding to the hydrophobic
prenyl groups attached to the C-termini of the PDE6 catalytic subunits (Cook et al.,
2000). Because hydrophobic interactions may stabilize GARP2-PDE6 interactions (see
above), we wondered whether PrBP/8 binding to PDE6 would solubilize the enzyme as a
complex with GARP2 or, alternatively, compete with GARP2 for binding to a
hydrophobic region on PDE6. Fig. 3.4 shows an experiment in which increasing amounts
of PrBP/5 are added to ROS membranes (containing bound PDE6 and GARP2), and the
solubilization of PDE6 monitored by centrifugal separation of bound and soluble PDE6.
While PDE6 catalytic and Py subunits are released from ROS membranes by PrBP/5 in a
concentration-dependent manner, GARP2 remains completely associated with ROS
membranes (Fig. 3.4).
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Figure 3.4. PrBP/5 selectively solubilizes PDE6 from ROS membranes while GARP2
remains on the membranes, free of PDE6 subunits. Purified ROS membranes were
incubated overnight at 4°C with indicated amounts of GST-PrBP/5 (relative to the PDE6
subunit concentration). Membranes were centrifuged and soluble (S) and membrane
fractions (P) were analyzed by immunoblotting using a GARP2-specific antibody, the
PDE6 NC antibody, and the Py CT-9710 antibody.
This effect of PrBP/5 to disrupt GARP2-PDE6 interactions is not restricted to PDE6
associated with ROS membranes. If PDE6 and GARP2 are first released from ROS
membranes by hypotonic extraction and then PrBP/8 is added, some of the GARP2 that
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normally co-migrates with PDE6 at -300 kDa during gel filtration chromatography is
now observed eluting at an apparent molecular weight of -60 kDa (data not shown). The
disruption of GARP2-PDE6 interactions by PrBP/ 8 suggests that one site of interaction
may be at the hydrophobic isoprenyl groups at the C-termini of PDE6 catalytic subunits.
It is possible that this same binding interface may be disrupted during hydrophobic
interaction chromatography.

Purified, native GARP2 suppresses basal PDE6 catalytic activity, but does not
inhibit activated PDE6—It was previously reported that GARP2 potently inhibited PDE6
hydrolytic activity when purified PDE6 was activated by transducin in solution; in
contrast, trypsin-activated PDE6 (lacking Py) or nonactivated enzyme (aPyy) were not
greatly affected by GARP2 (Korschen et al., 1999). However, Korschen et al. used a
recombinant GARP2 fusion protein for these experiments, and unpublished results from
the same group have called into question the ability of native GARP2 to inhibit
transducin-activated PDE6 (Kaupp and Seifert, 2002). Furthermore, transducin activates
PDE6 more effectively when both proteins are associated with the disk membrane
compared to activation in solution (Fung and Nash, 1983; Bruckert et al., 1994).
‘Therefore, we chose to examine whether native, purified GARP2 exerted an effect on
nonactivated or activated PDE6 under more physiological conditions in which PDE6
remains associated with the disk membrane.
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Figure 3.5. GARP2 suppresses nonactivated PDE 6 activity but is ineffective with
activated PDE 6 . Bovine ROS homogenates (10 nM PDE6 ) were either trypsin-activated
(tPDE), transducin-activated by addition of 10 pM GTPyS (taPDE), or maintained in a
non-activated state (nPDE), as described in Experimental Procedures. Purified GARP2
was added to each sample in an amount referenced to the amount of endogenous GARP2
present in these ROS membranes (see Experimental Procedures). For each experimental
condition, catalytic activity was normalized to the PDE6 activity in the absence of
exogenous GARP2 (defined as zero on the x-axis): 87 ± 19 (n = 9), 398 ± 105 (n = 5),
and 4260 ± 680 (n = 4) cGMP hydrolyzed per PDE6 per sec for nonactivated PDE,
transducin-activated PDE, and trypsinized PDE, respectively.

As seen in Fig. 3.5, addition of purified, native GARP2 to nonactivated PDE6
attached to ROS membranes (which contain endogenous GARP2) inhibited the basal rate
of PDE6 activity by 80%. The suppression of PDE6 activity by GARP2 was maximal
when an amount of purified GARP2 was added equal to its endogenous level in ROS (as
determined by quantitative immunoblot analysis). A similar result was obtained with
purified PDE6 that had been extracted from ROS membranes and chromatographically
purified (data not shown).
In contrast, no significant effect of GARP2 on either transducin-activated PDE6
(attached to ROS membranes) or trypsin-activated PDE6 was seen (Fig.3.5). Even
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following addition of a 10-fold excess of purified GARP2 relative to its endogenous
concentration in ROS membranes, the PDE6 activity of both transducin- and trypsinactivated PDE6 remained within 20% of its activity in the absence of GARP2. While the
results in Fig. 3.5 for trypsin-activated PDE6 are in accord with those of Korschen et al.,
we failed to observe the inhibitory effect of GARP2 on transducin-activated PDE6 that
they reported (Korschen et al., 1999).
To more sensitively test whether GARP2 influences the ability of transducin to
activate PDE6 , we first supplemented light-exposed ROS membranes with either GARP2
or nothing, and then added increasing amounts of GTPyS to persistently activate
transducin in a concentration-dependent manner.
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Figure 3.6. Inability of GARP2 to reduce activation of PDE6 by transducin. ROS
homogenates (1.5 nM PDE6 ) were first incubated with either a 2-fold excess of GARP2
relative to its endogenous concentration (+GARP2) or buffer (-GARP2). The ROS
membranes were exposed to light, and then the indicated amount of GTPyS was added to
persistently activate transducin. The PDE6 activity is normalized to the extent of
activation by saturating amounts of GTPyS, compared to the nonactivated PDE6 rate
(150 or 110 cGMP per PDE6 per s in the absence or presence of GARP2, respectively).
The data represent the mean ± S.E.M. (n = 3).

74

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

Fig. 3.6.(Rechsteiner and Rogers, 1996) shows that in the presence of GARP2 (at a
concentration two-fold greater than required'to maximally suppress PDE6 basal activity),
the ability of transducin to activate PDE6 is only slightly impaired; the small decrease in
activation at any given GTPyS concentration was not statistically significant. Once
sufficient GTPyS was added to activate all of the transducin present (the transducin: PDE6
ratio in bovine ROS being 30:1), adding more GTPyS had no further effect on PDE6
activation in the absence or presence of GARP2.
This result shows that the activity-lowering effect of GARP2 on the nonactivated
PDE6 holoenzyme is distinct from the molecular events by which the activated a-subunit
of transducin binds to PDE6 and displaces its Py subunit, thereby causing light activation
ofPDE 6 .

Proposed physiological role fo r GARP2 regulation o f PDE6 in rod photoreceptors—In
this study, we have shown that GARP2 is a high-affinity PDE6 regulatory protein capable
of suppressing the basal activity of nonactivated PDE6 , but with negligible effects on
transducin-activated PDE6 . The exclusive localization of GARP2 to rod outer segments
(Colville and Molday, 1996; Korschen et al., 1999) suggests that this protein may
regulate rod PDE6 in a way that helps distinguish the rod and cone phototransduction
pathways. One feature that differentiates rods from cones is the amplitude o f fluctuations
in the dark current (“dark noise”) in the photoreceptor outer segment (Rieke and Baylor,
1996; Rieke and Baylor, 2000). The low dark noise of rods permits reliable signaling at
the single photon level (Baylor et al., 1979), whereas cones require several photons to
generate a detectible signal (Schnapf et al., 1990).
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Because the rates of PDE6 activation/inactivation determine the characteristics of
photoreceptor dark noise (Holcman and Korenbrot, 2005), GARP2 is an attractive
candidate for regulating rod PDE6 to lower its spontaneous activation. This study
suggests that binding of GARP2 to nonactivated rod PDE6 will lower its catalytic
activity, most likely by enhancing the affinity of Py for the active site of the enzyme. The
observed localization of GARP2 to the rim of the disk membrane in ROS (Colville and
Molday, 1996; Korschen et al., 1999) may serve as a mechanism to reduce spontaneous
PDE6 activation and thereby minimize fluctuations in cGMP concentrations in the
vicinity of the cGMP-gated ion channel.
The lack of an effect of GARP2 on transducin-activated PDE6 is also consistent
with the need for rod PDE6 to be rapidly and stoichiometrically activated upon binding of
activated transducin. The single photon sensitivity of rod photoreceptors would likely be
impaired if GARP2 were to reduce the efficiency of PDE6 activation by transducin. In
summary, our results support a role for GARP2 in maintaining a very low spontaneous
activation of PDE6 without interfering with the efficiency of the visual excitation
pathway in rod photoreceptors in response to photic stimuli. Reports that GARP2 is
associated with the disk rim protein, peripherin (Poetsch et al., 2001; Batra-Safferling et
al., 2006), leave open the intriguing possibility that GARP2 might preferentially regulate
PDE6 in the vicinity of the cGMP-gated channel where cGMP,metabolic flux might be
most stringently controlled.
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Summary
This paper demonstrates that GARP2 is a novel PDE6 interacting protein that is
capable of regulating the basal activity of the PDE6 holoenzyme in rod outer segments.
The high affinity with which it binds nonactivated PDE6 suppresses catalytic activity
without adversely affecting the ability of transducin to activate PDE6 . This novel
regulatory mechanism may be of fundamental importance in establishing the high signalto-noise ratio needed for single photon detection in rod photoreceptors. Future studies
will be directed toward determining the molecular mechanism of GARP2 interaction with
the catalytic and/or inhibitory subunits of dark-adapted and light-activated PDE6 .
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CHAPTER 4

MULTIPLE SITES OF INTERACTION OF GARP2 WITH PDE6
HOLOENZYME AND MECHANISM OF REGULATION6

Abstract

Rod photoreceptors are unique in their ability to detect a single photon of light.
However, at high light intensities, rod photoreceptor photoresponses are saturated and
under these conditions electrical responses are generated only by cone photoreceptors.
Some of the differences in the physiological responses of rods and cones can be attributed
to proteins expressed exclusively in one type of photoreceptor cells. Previously, it has
been shown that rods contain a class of proteins not found in cones, specifically the
Glutamic Acid-Rich Proteins (GARPs). One of these proteins, GARP2, interacts with

The abbreviations used are: PDE, phosphodiesterase (E.C. 3.1.4.35); PDE6 , retinal
photoreceptor PDE; PDEaP, catalytic heterodimer of rod PDE6 ; Py, inhibitory 10 kDa
subunit of rod PDE6 ; GARP, glutamic acid-rich protein; rGARP2, recombinant glutamic
acid-rich protein 2; Ta, a-subunit of the rod photoreceptor G-protein, transducin; ROS,
rod outer segment; SDS-PAGE, sodium dodecil sulfate polyacrylamide gel
electrophoresis; nPDE, nonactivated PDE6 ; tPDE, trypsin-activated PDE6 ; taPDE,
transducin-activated PDE6 ; GTPyS, guanosine 5'-0-[3-thiotriphosphate]; IPTG,
isopropyl-beta-D-thiogalactopyranoside.
6
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high affinity with PDE6 , and lowers the basal rate, or “dark noise” of rod photoreceptors,
contributing to the high light sensitivity of these cells. However, GARP2 does not have
an effect on the ability of transducin to activate PDE6 . Here we show that GARP2
interacts with PDE6 only at specific stages of the activation-inactivation cycle of PDE6 .
GARP2 is able to influence the PDE6 basal rate by increasing the inhibitory PDE-gamma
subunit affinity for the PDE6 catalytic dimer. We propose that GARP2 interacts at
several sites on the PDE6 holoenzyme to affect allosteric control of PDE6 activity in the
dark-adapted, but not light-adapted state.
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Introduction

The presence of the Glutamic Acid-Rich Proteins (GARPs) in rods and their
absence in cones (Korschen et al., 1999; Colville and Molday, 1996) suggest an unique
role for GARPs in the physiological response of rod photoreceptors (see Chapter 1)
versus cones response. The GARP family of proteins consists of the P-subunit of the
cGMP-gated channel, and two splice variants: GARP1 and GARP2. All three members of
the GARP family are alternative transcripts the same gene, located on human
chromosome 16 (Ardell et al., 1996). Recent studies show that GARP2 has a natively
unfolded structure and exists in a monomer-multimer equilibrium (Batra-Safferling et al.,
2006). These physical characteristics suggest that GARP2 might have a role in
maintaining the structure of rod photoreceptor outer segment, serving as a linker between
the plasma membrane and the disk rims (Batra-Safferling et al., 2006). GARP2 has four
proline-rich regions (Colville and Molday, 1996; Korschen et al., 1995) that might be
responsible for interacting with other proteins of the rod outer segment (Korschen et al.,
1999). However, it appears that GARP2 makes high-affmity interactions only with PDE6
(Korschen et al., 1999; Pentia et al., 2006) and with peripherin-2 (Poetsch et al., 2001).
Interaction with peripherin-2 might serve for anchoring the plasma membrane channel to
the rod disks (Poetsch et al., 2001). The high content of glutamic acid, and the presence
of the glutamic acid-rich region in GARP1 and the P subunit of the cGMP-gated channel
confer to all GARPs their abnormal electrophoretic mobility (Sugimoto et al., 1991;
Ardell et al., 1995; Colville and Molday, 1996).
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We demonstrated in a previous study that GARP2 interacts with PDE6 with high
affinity, and upon this interaction the basal activity, or the “dark noise” of PDE6 is
reduced (Pentia et al., 2006). However, we could not detect any influence of GARP2 on
activated PDE6 . This finding might suggest that GARP2 exerts its effect by interacting
with the inhibitory Py subunit of PDE6 , since the activation of PDE6 requires the removal
of the inhibition by Py. We hypothesize that GARP2 enhances the affinity of the
inhibitory Py subunit to PDEaP, lowering the PDE6 basal rate and conferring rod
photoreceptors greater sensitivity for light stimulus.
Enzymatic catalysis of PDE6 is regulated by its inhibitory Py subunit. The
interaction between the inhibitory subunit Py and PDEaP is complex, with multiple sites
of interaction (Artemyev and Hamm, 1992; Artemyev et al., 1996a; Granovsky et al.,
1997; Granovsky et al., 1998; Natochin and Artemyev, 1996). The N-terminal half of Py
contains a polycationic region (amino-acids 20-45) which makes a high-affinity
interaction with the cGMP binding GAF domain of PDEaP (Artemyev and Hamm, 1992;
Lipkin et al., 1993; Natochin and Artemyev, 1996). This interaction is stronger when the
GAF domains are occupied by cGMP, and weaker when they are empty (Mou and Cote,
2001). The C-terminus region of Py makes direct contact with the catalytic domain of
PDEaP imparting the inhibitory effect on catalysis (Skiba et al., 1995; Granovsky et al.,
1997). There is no evidence that allosteric binding of cGMP to the regulatory GAF
domains directly regulates the catalytic activity of PDE6 . However, the binding affinity
of Py to the PDEaP is allosterically regulated by the occupancy of the GAF domains by
cGMP (Cote et al., 1994; Yamazaki et al., 1982; Norton et al., 2000; Mou et al., 1999;
Mou and Cote, 2001).
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Membrane-associated PDE6 holoenzyme has two high-affinity cGMP binding
sites (Gillespie and Beavo, 1989). The two sites however are not identical in their binding
affinity for cGMP, one site becoming exchangeable and decreasing its binding affinity by
more than 100 fold upon the removal of Py, while the second cGMP binding site has only
a slightly lower binding affinity (Mou et al., 1999). It appears that Py binding to PDEaP
occurs as a two step process, one Py binds with high affinity (KD< 0.3 pM), while the
second Py affinity is much lower (K d = 7 pM). It is hypothesized that the high affinity Py
binding site is correlated with the high affinity cGMP binding site at the GAF domains
(Mou and Cote, 2001). Py also makes interactions with Ta-GTP at the C-terminal region
of Py (amino-acids 77-87) and at the poly-cationic region (Artemyev et al., 1992;
Artemyev and Hamm, 1992; Slepak et al., 1995; Slep et al., 2001). The C-terminal region
of Py has a much lower affinity for PDEaP (Mou and Cote, 2001). The C-terminus of Py
can interact with the GTPase activating protein RGS9 at the amino-acid Trp70 (Slep et
al., 2001; Tsang et al., 1998; Slepak et al., 1995). Following this interaction, the GTPase
activity of RGS9 is enhanced, Py serving as a GTPase activating protein (GAP;
(Arshavsky et al., 1994; Angleson and Wensel, 1993).
In its non-activated state, PDEaP catalytic sites are blocked by two Py inhibitory
subunits. PDE6 is activated by the binding of activated transducin (Ta-GTP) to the Cterminus region of the inhibitory Py subunit (Yamazaki et al., 1983; Yamazaki et al.,
1990; Wensel and Stryer, 1990; Wensel and Stryer, 1986; Gray-Keller et al., 1990), and
subsequent exposure of the catalytic site, enabling the hydrolysis of cGMP. Experimental
evidence suggests that Ta-GTP can only activate one catalytic site of the PDE6
heterodimer (Melia et al., 2000; Norton et al., 2000). Following activation, the cGMP
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level concentration drops, increasing the likelihood that the cGMP bound to the GAF
domains will dissociate (Mou et al., 1999). The relative binding affinity of Py-Ta-GTP
complex for PDEaP decreases upon cGMP release from the GAF domain, allowing the
dissociation of Py-Ta-GTP complex (Cote et al., 1994). This dissociation may promote
the GTPase activating protein (GAP) activity of Py (Arshavsky and Bownds, 1992).
Upon Ta deactivation, Py is released and is able to re-inhibit PDEaP and revert to the
non-activated state. The cycle of PDE6 activation and inactivation is summarized in Fig.
4.1.
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Ta-GTI

non-activated PDE6

Ta-GDP
Ta-GTI
activated! PDE6

Ta-GTP

+ Ta-GDI
Figure 4.1. PDE6 activation-deactivation cycle.
State 1. Dark-adapted state: PDE6 has two Py subunits bound, and the GAF
domains are occupied by cGMP.
State 2. Initial transducin-activated state: Ta-GTP interacts with Py and releases
inhibition at one catalytic site. cGMP still occupies the GAF domains.
State 3. Persistent transducin-activated state: as cGMP levels remain low, one GAF
domain rapidly releases cGMP (the second GAF domain releasing bound cGMP more
slowly). This enhances release of Ta-GTP-Py from PDE6 . Subsequently, GTP is
hydrolyzed to GDP and Py dissociates from Ta-GDP.
State 4. Py re-associates with PDEaP, but cGMP levels are still low and GAF domains
remain empty until cGMP levels are restored to dark levels.
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The goal of this study is to identify the steps of the PDE6 activation-deactivation
cycle that are able to bind GARP2 and the sites of interaction of GARP2 with PDE6
holoenzyme. We hypothesize that GARP2 interaction takes place primarily with Py,
enhancing its affinity to bind to PDEaP and thereby reducing the probability of
spontaneous activation of non-activated PDE6 and lowering the basal rate of PDE6
activity (Pentia et al., 2006). We further speculate that efficient activation of PDE6 by
transducin requires dissociation of GARP2 from PDE6 upon light activation. Therefore
we analyze the interaction sites of GARP2 with PDE6 holoenzyme during the different
activation conditions.
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Materials and Methods

1. Materials:
Bovine retinas were purchased from W. L. Lawson Co, Lincoln, NE. [3H]cGMP
was purchased from PerkinElmer Life Sciences. Ultima-Gold scintillation fluid was
obtained from Perkin Elmer. Membranes for filter binding assays were purchased from
Millipore. Reagents and substrates for immunoblots were from Pierce and Bio-Rad. 6 His-tagged recombinant GARP2 plasmid was a kind gift from Dr. Benjamin Kaupp
(Julich, Germany). All other chemicals were obtained from Sigma. Antibodies used were:
anti-NC, N-terminal half of PDE6 catalytic subunit; anti-CT, C-terminal Py; anti Ta,
from Affinity Bioreagents; and anti-GARP2, a kind gift of Dr. Benjamin Kaupp.

2. Expression and purification o f recombinant GARP2.
The GARP2 protein used in these studies was expressed as a 6 His-flagged
recombinant protein in E. coli cells. The rGARP2 plasmid, a kind gift for Dr. Benjamin
Kaupp (Julich, Germany), was cloned between restriction sites EcoRI and Hindlll of the
pET30a vector. The vector was transformed in E.coli BL21 competent cells following
standard procedures. Glycerol stocks were generated from the transformed cells. Initial
colonies of plasmid containing E.coli cells were grown from the glycerol stock on a
kanamycin plate. A single colony from the plate was inoculated in a LB medium
containing 50 pg/ml kanamycin, and incubated with shaking overnight at 37°C. The
following morning, 10 ml from the overnight culture were inoculated into two 500 ml
2xTY media also supplemented with 50 pg/ml kanamycin. The cells were incubated with
shaking at 20°C for 4 hours, until the ODeoo reached 0.6-0.8. Protein expression was then
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induced by addition of 1 mM IPTG. Additional 3 hours incubation at 20°C allowed the
expression of full-length GARP2 protein. These expression conditions were found to be
optimal for obtaining full-length rGARP2 that runs on SDS-PAGE at an apparent MW of
60kDa. A higher incubation temperature produces truncated proteins (see Fig. 4.2.).
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Figure 4.2. Conditions for optimal expression of rGARP2.
E. coli cells harboring the rGARP2 plasmid were tested for rGARP2 expression by
incubating at 20°C and 37°C for various times. The cells were then lysed and the
supernatants and pellets were analyzed by western blot using full-length anti-GARP2
antibody.
Cells were pelleted by centrifugation and resuspended in His-Bind binding buffer
supplemented with EDTA-ffee protease inhibitors. To disrupt the cells, two freeze- thaw
cycles followed by two sonication bursts were used. The lysate was centrifuged for 30
min at

1 0 0 ,0 0 0

x g, and the supernatant was recovered.
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Recombinant GARP2 was purified from the cells lysate by Ni-chelated affinity
method. The His-Bind resin (Novagen) was charged with a solution of 50 mM MSO4.
The column was equilibrated with 3 column volumes of binding buffer (0.5 M NaCl,
20mM Tris-HCl, pH 7.9). The bacterial extract was applied to the column at a flow rate
of 0.5 ml/min. The unbound material was washed with 10 column volumes of binding
buffer at a flow rate of 1 ml/min. Bound proteins were eluted with 2 column volumes of
elution buffer (0.5 mM NaCl, 20 mM Tris-HCl, pH 7.9,150 mM imidazole). Further
purification of recombinant GARP2 was required. The protein eluted from the His-Bind
column was dialyzed overnight in a low salt buffer (5 mM Tris, pH 7.5,100 mM NaCl, 1
mM DTT). The rGARP2 solution was applied to the MonoQ column, the unbound
proteins were washed with 5 column volumes of low salt buffer, and the bound proteins
were eluted with a linear gradient from 100-1000 mM NaCl in 5 mM Tris, pH 7.5. 1 ml
fractions were collected. The rGARP2 peak was detected by dot-blotting the fractions on
nitrocellulose membrane, and probing the membrane with anti-GARP2 C-terminus
antibody (Affinity Bioreagents).

2. PDE6 activity assays.
2.1 Colorimetric phosphate release assay.
The rates of cGMP hydrolysis catalyzed by activated and non-activated PDE6 were
measured by a coupled-enzyme phosphate release assay (Cote, 2000).
2.2 Radiotracer assay.
The assay is a coupled enzyme assay involving determination of the radioactive
[ H]guanosine that is generated by hydrolysis of [ H]cGMP by PDE6 which yields 5-
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[3H]GMP. Addition of snake venom to the assay solution causes the 5'-[3H]GMP to be
degraded to [3H]guanosine plus inorganic phosphate. Separation of [3H]guanosine from
un-reacted [ H]cGMP occurs by passage of the sample through an anion-exchange
column (DEAE-Sephadex) equilibrated with a low salt solution (20 mM Tris-HCl, pH
. ). This assay is much more sensitive than the colorimetric phosphate release assay, and

6 8

it gives good estimates for non-activated PDE activity. It is also suitable for very low
(pM) concentrations of activated PDE6 .

3. Preparing GARP2-free ROS membranes.
Sucrose purified bovine ROS membranes were resuspended in the dark in isotonic
buffer (10 mM Tris, pH 7.5, 100 mM NaCl, 2 mM MgCl2 , 1 mM DTT), and centrifuged
for 5 min at 130,000 x g to remove the soluble proteins. At this point, the ROS
membranes were exposed to light to ensure the tight binding of T a to the membranes.
The membranes were resuspended in the same isotonic buffer as above, supplemented
with 0.1% v/v Triton X-100. The solution was centrifuged for 5 min in the Airfuge at
130,000 x g. The supernatant contained all the GARP2, while the pellet contained PDE6
and Ta (Fig. 4.3.). The pellet was washed two times with isotonic buffer and centrifuged
as above in the Airfuge to remove any trace of detergent.
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Figure 4.3. Preparation of GARP2-free ROS membranes.
ROS membranes were treated with 0.1% Triton X-100 and the soluble portion (S) was
separated from membranes (P) by centrifugation for 5 min at 130,000 x g. The control
sample was treated with isotonic buffer. Following detergent treatment, the membranes
were washed of residual detergent with isotonic buffer (W). Resulting samples were
analyzed by western blot using anti- full-length GARP2 antibody and anti- catalytic
subunit PDE6 antibody.
4. Preparation o f recombinant PyFL, Pyl-45, and Py63-87.
Full-length bovine rod Py and the N-terminal fragment consisting of the first 45
amino-acids (Pyl-45) were expressed in E. coli cells using a pETl la expression vector
(Slepak et al. 1995) and purified as described elsewhere (Artemyev et al., 1998). Briefly,
the bacterial extract was purified on a cation exchange column (SP-Sepharose, GE
Healthcare), and the protein of interest (Py or Pyl-45) was chromatographed on a semi
preparative C4 reverse-phase column (300 A,

10

x 250 mm) using a linear gradient of 30-

80% acetonitrile in 0.1% trifluroacetic acid. The concentration of full-length Py was
routinely measured spectrophotometrically (6 2 7 7 = 7550 cm' 1 M'1; (Cote, 2000). The
concentration of purified Pyl-45 was measured using the bicinchoninic acid protein assay
(Smith et al.,1985). Py63-87 was purchased commercially, and purified by reverse-phase
high pressure liquid chromatography on a preparative C4 column (Vydac), using a linear
gradient of 30-80% acetonitrile. After lyophilization, the peptide was resuspended in 10
mM Tris, pH 7.5, and its concentration determined by the bicinchoninic acid protein

90

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

assay (Smith et al., 1985) using bovine serum albumin as the standard. The inhibitory
capacity of purified Py was verified by PDE6 activity assays.

5. Pull-down assay o f P/-interacting proteins 'with Py beads.
Py peptides and full length Py were prepared as described above. The proteins
were coupled to CNBr-activated Sepharose according to the manufacturer's protocol (GEHealthcare). rGARP2 (10 pL of 100 pM) was incubated with 10 pL of settled beads in a
final volume of 200 pL of TMN buffer (50 mM Tris, pH 7.5, 140 mM NaCl, 0.5 mM
MgCl2 , 0.2 mM Pefabloc) for 4 hours at 4°C with rocking. After the incubation, the
supernatant was spun and removed, and the beads were washed two more times with 1
mL of ice-cold TMN buffer. After the washes, the beads were treated with 20 pL of gel
sample buffer, heated for 5 min at 85°C, and the extract removed by centrifugation. The
collected samples were run on a 12% acrylamide SDS-PAGE, transferred to
nitrocellulose membrane, and probed with the relevant antibodies.

6. Measurements o f cGMP binding to the non-catalytic GAF domains o f PDE6.
A membrane filtration assay was used to determine the amount of radiolabeled
cGMP bound to the non-catalytic sites of PDE6 (Cote, 2005). Given the high affinity
nature of cGMP binding to PDE6 (Kp<pM) (Cote et al., 1994; Cote and Brunnock, 1993)
this method offers high sensitivity, good partitioning of free from bound ligand, and low
non-specific binding. Some precautions needed to be taken. First, all the endogenous
cGMP that was bound to the GAF domains was destroyed by incubating PDEaP at 30°C
for 4 hours. Because cGMP is both a ligand for the non-catalytic GAF domains and
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substrate for the catalytic domain, a second precaution was to block the catalytic sites by
using a selective inhibitor (zaprinast) at 1 mM. The binding reaction was initiated by
addition of [3H]cGMP solution to the depleted PDEap. Immediately following cGMP
addition, Py was added to some samples stabilize the low affinity cGMP binding site.
Samples were applied to pre-wet nitrocellulose membranes over a vacuum filtration
device, and unbound ligand was rinsed with 3 x 1 ml washes of isotonic buffer (100 mM
Tris, pH 7.5,1 mM EDTA). The membranes were placed in scintillation vials, mixed
with scintillation fluid and the total counts were measured in the scintillation counter.

7. Preparation o f lipid rafts from bovine ROS membranes.
Purified ROS membranes were resuspended in an isotonic buffer (10 mM MOPS,
pH 7.2, 60 mM KC1, 30 mM NaCl, 5 mM MgCb, lmM DTT). The samples used for
analyzing lipid domains in the non-activated state were kept in the dark for the entire
duration of the experiment; otherwise, the ROS membranes were exposed to light, and
treated with the required nucleotides. The resuspended ROS samples were treated with
Triton X-100, (final concentration of 1% v/v). The ROS membranes were then
homogenized with 10 passes of a glass homogenizer. The homogenized ROS membranes
were incubated on ice for 10 minutes, and adjusted to 0.9 M sucrose using a 2.4 M
sucrose solution. The sucrose ROS solution was placed on the bottom of a 17 ml ultra
centrifuge tube, and was overlaid with sucrose solutions of the following concentrations:
0. 8 M, 0.7 M, 0.6 M and 0.5 M. The tubes were placed centrifuged for 20 hours at
100,000 x g. At the end of the spin, the Triton X-100 insoluble lipid domains separated at
the interface of the 0.5 M and 0.6 M sucrose layers. Fractions of 500 pL were collected
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from the top of the tube. Fractions were analyzed for PDE6 activity using a colorimetric
assay and rhodopsin concentration was measured by monitoring light absorbance of each
fraction at 500 nm (Bownds et al., 1971). Detergent-insoluble lipid domains were also
detected from the turbidity of the samples by monitoring light absorbance at 600 nm.
Proteins of interest (GARP2, PDE6, Ta) were detected by western blot analysis.
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Results and Discussion

1. GARP2 enhances P y affinity for PDEafi
Our previous study showed that GARP2 is able to reduce the spontaneous
activation of PDE6, thereby reducing the basal rate of PDE6 activity (Pentia et al., 2006).
One possible mechanism by which GARP2 has this effect is by enhancing the binding
affinity of the inhibitory Py subunit for PDE6. It is more likely that GARP2 inhibitory
effect takes place through Py than by direct inhibition of GARP2 on PDE6 catalysis,
because GARP2 is not able to inhibit PDEaP catalytic dimer by itself. There is no
observed inhibition on either trypsinized PDE6 or transducin-activated PDE6 (Pentia et
al., 2006). In order to determine whether GARP2 effect on catalysis is a result of the
altered affinity of Py to PDEaP, Py affinity was measured in the presence and absence of
GARP2.

1.1. Preparation o f GARP2-free ROS membranes.
To more closely mimic the physiological situation in which PDE6 is membrane
associated, these experiments were carried out using purified bovine ROS membranes
diluted in an isotonic buffer (see Materials and Methods). To determine the effect of
GARP2 on Py affinity for PDEap, ROS membranes had to be stripped of their
endogenous GARP2. We developed a protocol that selectively removed GARP2 from
ROS membranes, using low concentrations of the detergent Triton X-100. Several
concentrations of detergent were initially tested (see Fig. 4.4.), ranging from 0.1% to 1%
v/v Triton X-100. GARP2 was released almost completely even at 0.1% Triton X-100.
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As the concentration of detergent increased, PDE6 started to be released also. The
concentration of 0.1% Triton X-100 was chosen to elute GARP2 from ROS membranes
without elution of significant amounts of PDE6. After the removal of soluble GARP2 in
detergent, the ROS membranes were washed two times in isotonic buffer to remove any
trace of detergent and contaminating GARP2.

S

0%
P

S

0.1%
P

S

0.2%
P

S

03%
P

%TX-!00
T

DARK

0%

0.1%

02%

0.3%

%TX-1G0
PDEap
GARP2

LIGHT

Figure 4.4. Determining conditions that release endogenous GARP2 from ROS
membranes with minimum loss of PDE6 or Ta. Light-exposed ROS membranes were
washed first with isotonic buffer and centrifuged for 5 min at 130,000 x g to remove
soluble proteins. The resulting pellets were incubated with the indicated concentrations of
the detergent Triton X-100 for 5 min at room temperature, and centrifuged again to
separate the detergent-soluble fraction (S) from the pellet (P). The resulting samples were
resuspended in gel sample buffer, and equivalent volume samples were subjected to SDSPAGE. The separated proteins from the gel were transferred to nitrocellulose membrane,
and separately identified with specific antibodies: anti-PDENC, anti-FL-GARP2 and antiTa.
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1.2. Measuring the binding affinity o f Pyto PDEap.
Previous work showed that dilution of PDE6-containing frog ROS membranes
could be used as a way to estimate the Kd of Py binding to PDEap (D'Amours & Cote
1999). To measure the Py affinity for bovine PDEap and the effect of GARP2, Py
dissociation was induced by diluting the bovine PDE6 holoenzyme, thereby shifting the
binding equilibrium towards dissociation:

PDEaP + 2Py <-> PDEaPyy

The apparent affinity of bovine Py to PDEap is 10 pM (Wensel and Stryer, 1986) while
the Kd for frog Py is 28 pM (D'Amours and Cote, 1999). The PDE6 concentration chosen
for these experiments was in the range of 1 nM-10 pM. This range of concentrations
allows Py to dissociate, and the catalytic site to be exposed. The degree of dissociation
can be monitored by the increase in PDE6 catalytic activity, the greater the activity, the
more Py dissociates from PDEap. However, at concentrations lower than -5 pM, PDE6
activity can not be measured reliably, probably because of the enzyme degradation during
long incubation times that are required for such low concentrations. The high binding
affinity of Py for PDEap of bovine PDE6, and the instability of the PDE6 at low
concentrations made it difficult to observe the desired dilution effect. When frog ROS
was used, the activation of PDE6 was far greater than when bovine ROS was used (see
Fig. 4.5.). This comparison is direct experimental evidence that the affinity of Py for
PDEaP is greater for bovine ROS than it is for frog ROS. The activation of PDE6 for frog
ROS was -50% of Vmax at the lowest concentration tested (5 pM) while at the same
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concentration bovine ROS could only be activated up to 2%. Even so, a modest increase
in activity is observed in the ROS samples that lack endogenous GARP2 compared to
those that have not been depleted of GARP2.
To definitively determine that GARP2 indeed enhances the binding affinity of Py to
PDEap, a greater activity is needed to be observed for the dilution of ROS membranes.
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Figure 4.5. Comparison of frog and bovine ROS Py affinity for PDEap. Purified ROS
were first washed with an isotonic buffer to remove the soluble proteins. For bovine
ROS, one sample was treated with 0.1% Triton X-100 to remove endogenous GARP2.
That ROS sample was washed two more times with isotonic buffer to remove traces of
detergent. PDE6 concentration was determined for each ROS sample using an enzymatic
assay. Samples were diluted to the indicated concentrations in isotonic buffer, and were
incubated with 1 mM radiolabeled cGMP to analyze PDE6 activity with the readiotracer
assay. The rate was normalized to the value expected for fully activated PDE6 (v/Vmax).
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1.3. Using histones to destabilize Py binding to PDEafi.
Other research groups have reported the activation of PDE6 using histones
(Hurwitz and Beavo, 1984; Miki et al., 1975). Histones are also used for enhancing
cGMP binding to the GAF domains of PDE5 (Corbin et al., 2003; Gopal et al., 2001;
Weeks et al., 2005). The mechanism by which histones are able to bind to and regulate
PDE is not well understood. It is hypothesized that for PDE6, negatively charged histones
interact with the poly-cationic region of Py and displace Py from PDEap.
Upon addition of histone type II-AS the maximal dilution-induced activation of
PDE6 increased by approximately 10-fold (see Fig. 4.6.).
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Figure 4.6. Improving conditions for Py dissociation from PDEafi upon dilution.
Bovine ROS membranes were first washed with isotonic buffer to release soluble
proteins. Half of the samples were treated with 0.1% Triton X-100 to release endogenous
GARP2, the other half being re-suspended in isotonic buffer. Samples were washed two
more times in isotonic buffer. PDE6 concentration was determined using an enzymatic
assay. Portions of each ROS sample were supplemented or not with 2.5 mg/ml histone
type II-AS. Samples were incubated with 1 mM radiolabeled cGMP to determine PDE6
activity. The experiment is representative of four experiments done under similar
conditions.
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A concentration of 15 pM was chosen for determining the effect of GARP2 on the
Py dissociation from PDEap. Adding recombinant GARP2 to ROS membranes depleted
of their endogenous GARP2 caused a decrease in catalytic activity (see Fig. 4.7.). The
activity of the GARP2-depleted ROS membranes at 15 pM PDE6 concentration is -70%
of that of ROS membranes fully activated by trypsinization, and -60% for the
membranes that still have the entire pool of endogenous GARP2 (see Fig. 4.7.). As the
recombinant GARP2 concentration is increased, the PDE6 activity decreases, with a
more pronounced effect in the case of the ROS membranes that have been depleted of the
endogenous GARP2, and less for those that contain the endogenous GARP2.
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Figure 4.7. Addition of exogenous GARP2 enhances Py affinity.
The activity of 15 pM PDE6 holoenzyme was determined for control (containing
endogenous GARP2) or GARP2-depleted ROS membranes to which the indicated
amount of recombinant, purified GARP2 was added. PDE6 activity was measured using a
radiotracer assay, and was expressed as percentage of the maximum rate for trypsinactivated PDE6 (Vmax = 5600 cGMP/s per PDE6). The experiment was performed once.
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2. GARP2 regulates cGMP binding to the GAF domains o f PDE6.
The effect of GARP2 on the catalytic activity of PDE6 holoenzyme suggested that
GARP2 might also affect the cGMP binding to the regulatory GAF domains. As
mentioned earlier, the regulatory GAF domains bind cGMP with different affinities: one
site is a high affinity site binding cGMP with a Kd of ~ 60 nM, while the second cGMP
binding site has a lower affinity (Mou et al., 1999). Upon Py interaction with PDEap, this
low affinity cGMP binding site is able to convert to a high affinity binding site.
Moreover, the binding of cGMP to the GAF domains also reciprocally regulates the
affinity of Py binding: when the GAF domains are occupied by cGMP, Py has a higher
binding affinity for PDEap (Mou & Cote 2001). Therefore, we hypothesized that GARP2
might not only modulate the affinity of the interaction between Py and the PDEap active
site, but also affect the cGMP binding to the GAF domains.
To determine whether GARP2 influences the binding affinity of cGMP to the
non-catalytic GAF domains of PDEaP dimer, a filter binding assay was used. Briefly,
PDE6 holoenzyme was mildly trypsinized to remove the inhibitory Py subunits. The
resulting PDEaP was incubated for 4 hours at 30°C to permit the endogenous cGMP that
was bound to the GAF domains to dissociate and be hydrolyzed. The catalytic sites were
then blocked by using a specific inhibitor (zaprinast 100 pM). A solution of 1 pM
radiolabeled cGMP was added to 5 nM PDEap. The influence on the low affinity binding
site was determined by adding recombinant Py in the absence or presence of recombinant
GARP2. In a different set of experiments, the influence of GARP2 on the cGMP binding
to the GAF domains was measured in the presence of recombinant Pyl-45 peptide (the Nterminal half of Py that induces high-affinity interactions with the GAF domains).
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In the absence of Py, cGMP binds to PDEap in a molar ratio of 1:1, as seen
previously (Mou et al., 1999). The addition of GARP2 appears to lower somewhat the
affinity of cGMP for the PDEap heterodimer (Fig. 4.8.). This suggests that GARP2
might modulate cGMP binding to the GAF domains by direct interactions with the
PDEap dimer.
In the presence of Py, addition of rGARP2 reverses the increase in affinity for
cGMP to the Py-dependent cGMP binding site. The same effect is observed if the Nterminus Py peptide is used (Pyl-45) (data not shown). This finding suggests that GARP2
has a destabilizing effect on Py affinity for the sites on PDEap that are responsible for
cGMP binding to the GAF domains. However, this is an indirect assessment of the Py
affinity, based on the regulatory effect that Py has on cGMP binding to the GAF domains.
In summary, these results would imply that GARP2 is able to interact with PDE6
holoenzyme at multiple sites of interaction. Some GARP2 interactions likely stabilize Py
interaction with the active site, while other sites of interaction of GARP2 may destabilize
cGMP binding to the GAF domains.
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Figure 4.8. GARP2 reduces cGMP binding to a high-affinity site on Pap, and
reverses the Py-dependent binding of cGMP to a second, lower affinity site.
cGMP binding to the GAF domains of PDE6 catalytic dimer (5 nM) in the presence or
absence of 70 nM Py and/or 5 nM recombinant GARP2 was measured with a membrane
filtration assay. This result is representative of 4 different experiments.

3. Defining the sites o f interaction o f GARP2 with Py.
Previous experiments have determined that GARP2 influences PDE6 properties
primarily by interacting with the inhibitory Py subunit. The reduction of PDE6 activity
following the shifting in Py binding equilibrium to PDEaPy2 could suggest that GARP2
interacts with the C-terminus part of Py, the part that interacts with the catalytic site on
the catalytic subunit. Also the change in cGMP binding affinity to the GAF domains
might suggest that GARP2 also interacts with the N-terminus part of Py, the part that
makes direct contact with the GAF domains. Direct evidence of GARP2 interacting with
Py is needed to determine that the interaction is indeed taking place.
A pull-down experiment was devised to directly determine if GARP2 is able to
interact with full-length Py and Py fragments. The N-terminal Py peptide Pyl-45, the C-
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terminal peptide Py63-87 and full-length Py were purified as described in Methods. The
peptides and protein were coupled to Sepharose beads and incubated with recombinant
GARP2 for 1 hour. The beads containing Py binding proteins were washed with an
isotonic buffer, and the protein complex was eluted with SDS-PAGE sample buffer. The
proteins were analyzed on western blots probed with anti-GARP antibody.
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Figure 4.9. GARP2 is pulled down by Py and its N-terminal and C-terminal
domains.
Purified GARP2 was incubated with full-length Py and the indicated Py peptides
immobilized to CNBr-activated Sepharose beads. After centrifugation, the pellet was
solubilized, loaded on SDS-PAGE, and an immunoblot performed using GARP2
antibody which recognizes the full-length protein. Control beads failed to pull down
GARP2.

GARP2 was found to bind to both Py peptides, as well as to the full-length Py
(Fig.4.9.). Previous experiments determined indirectly that GARP2 is able interact at
multiple sites with the Py subunit of PDE6. The pull-down experiment is direct evidence
that these interactions take place, and that GARP2 and Py interaction is a multiple region
interaction. What is missing are controls showing no non-specific binding of GARP2 to
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the beads in the absence of Py or fragments. The best control would be scrambled Py
peptides to show specificity.

4. Separation o f PDE6 and GARP2 during the light activation cycle.
The above findings suggest that GARP2 has an inhibitory effect on PDE6 by
enhancing the Py affinity for PDEap. There is also the possibility that GARP2 interacts
directly with the PDEaP dimer. During light activation, however, activated transducin
(Ta-GTP) interacts with the C-terminus of Py and removes the inhibitory constraint on
the catalytic site. From electrophysiological and biochemical measurements (Pugh, Jr.
and Lamb, 1993; Lamb and Pugh, Jr., 1992) it has been established that transducin
activation of PDE6 is very efficient. In order to have a high efficiency of transducin
activation, any GARP2 regulatory effect may need to be absent. Possible mechanisms
that will contribute to reducing the GARP2 effect on PDE6 include: a competition
between Ta-GTP and GARP2 for binding to the C-terminus of Py, or a separation of
GARP2 from PDE6 and Ta-GTP upon activation. To test if GARP2 and PDE6-Py-TaGTP separate on the disk membrane, ROS membranes were separated using detergent
conditions that generate lipid "rafts", and then the protein composition of PDE6containing fractions was analyzed.
Lipid membranes are a fluidic mosaic of phospholipids, sphingolipids, cholesterol
and proteins. Some portions of the membrane can assemble in to more structured
domains, or lipid "rafts", which are structured domains enriched in cholesterol,
sphingolipids, and are abundant in the protein caveolin, a marker for these lipid "raft"
domains (Brown and London, 1998; Kurzchalia and Parton, 1999). Experimentally it has
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been noticed that lipid "rafts" are insoluble in 1% Triton X-100 detergent, this
constituting the method used for their separation.
In order to separate lipid "rafts" from ROS membranes, purified rod outer
segments were treated with 1% Triton X-100, and then separated by a sucrose gradient
centrifugation. Lipid "rafts", being more buoyant, were collected from a less dense
sucrose layer (see Methods), while the detergent-soluble portions of the membrane were
left in the most dense sucrose layer. Using this tool, lipid "rafts" separated from ROS
membranes were analyzed, and the proteins of interest detected. The light exposure
conditions for ROS membranes were controlled, so that one sample was kept in the dark
for the duration of the "rafts" separation, while another sample was exposed to light and
treated with the non-hydrolizable GTP analog, GTPyS, to induce a state of permanent
activation. Upon separation of the membrane fractions, GARP2 was found only in the
soluble parts of the ROS membranes, regardless of the state of activation of the
membranes. PDE6 however showed a movement towards the detergent-insoluble
membrane domains (or lipid "rafts") upon activation (Fig. 4.10.).
This result provides the first evidence that GARP2 and activated PDE6 may not
be in close proximity to each other, preventing a potential "short-cut" of the activation
pathway by GARP2's inhibitory effect on PDE6.
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Figure 4.10. Lipid "raft1' separation of ROS membranes. ROS membranes were
homogenized in 1% Triton X-100 + 0.9 M sucrose and placed on the bottom of a sucrose
step gradient: 0.9 M, 0.8 M, 0.7 M, 0.6 M and 0.5 M sucrose. After a 20 h centrifugation
at 100,000 x g, fractions were collected from the top of the gradient. The lipid “rafts” are
found at the interface of 0.5 M and 0.6 M sucrose. The bottom of the tube contains the
detergent soluble, non-“raft” fraction of the membranes. For the dark condition, the
experiment was conducted under infrared illumination. The light-activated ROS
membranes were exposed to light and 1 mM GTPyS for transducin activation. Western
blots detected the presence of PDE6 and GARP2 using the anti-catalytic subunit PDE6
antibody and the anti-GARP2 antibody. This is representative of 5 other experiments.

5. Regulation o f GARP2 effect on PDE6 by dissociation o f these binding partners upon
light activation o f PDE6.
Previously we showed that GARP2 can reduce the spontaneous activation of
PDE6 in the dark, contributing to the reduced dark "noise" of rod photoreceptors and
their enhanced light sensitivity. If GARP2 and PDE6 separate following transducin
activation, there must be a later step of the activation-inactivation cycle of PDE6 that
restores GARP2-PDE6 interaction in order for GARP2 to re-exert its inhibitory effect in
the dark state. To study the association -dissociation states of GARP2 and PDE6 during
the activation cycle, the different steps of the cycle had to be isolated (see Fig. 4.11.).
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Figure 4.11. Potential role of GARP2 in PDE6 activation-deactivation cycle.
State 1. Dark-adapted state: PDE6 has two Py subunits bound, and the GAF
domains are occupied by cGMP.
State 2. Initial transducin-activated state: Ta-GTP interacts with Py and releases
inhibition at one catalytic site. cGMP still occupies the GAF domains.
State 3. Persistent transducin-activated state: as cGMP levels remain low, one GAF
domain rapidly releases cGMP (the second GAF domain releasing bound cGMP more
slowly). This enhances release of Ta-GTP-Py from PDE6. Subsequently, GTP is
hydrolyzed to GDP and Pg dissociates from Ta-GDP.
State 4. Py re-associates with PDEap, but cGMP levels are still low and GAF domains
remain empty until cGMP levels are restored to dark levels.
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Upon activation by rhodopsin, transducin exchanges bound GDP for GTP, and the
Ta subunit dissociates from its py subunits. Ta-GTP interacts with the C-terminus region
of Py on the PDEaPyi heterotetramer, and displaces the inhibitory constraint of Py on the
catalytic site of PDE6. At the beginning of PDE6 activation, the cGMP level inside the
cell is relatively high, and the GAF domains of the PDE6 holoenzyme are occupied. The
occupancy of the GAF domains imposes a higher affinity of interaction for the Nterminus part of Py with PDEap, therefore, Py-Ta-GTP does not dissociate from the
PDEap. This is depicted as State 2 in the activation cycle diagram (see Fig. 4.11.). To
reproduce this activation state, the ROS membranes were first exposed to light, and the
non-hydrolysable GTP analog, GTPyS was used. Extra cGMP was added to the ROS to
ensure the occupancy of the GAF domains, and catalysis was inhibited with the PDE
inhibitor, zaprinast. The membranes were then treated with 1% Triton X-100, and the
soluble and insoluble parts were separated by centrifugation (see Methods). The protein
content of the two fractions was analyzed by western blotting. PDE6 content was also
determined by a PDE6 activity assay. Under this state of activation, -50% of PDE6
appears to migrate to the detergent-insoluble portion of the membrane, while GARP2
remains soluble in 1% Triton X-100 (see Fig. 4.12.).
The next step in the activation cycle of PDE6 is achieved when the cGMP
concentration drops inside the cell as a consequence of the catalytic activity of PDE6.
When the cGMP level is low, the cGMP bound to the GAF domains is released. This
release of cGMP from the GAF domains, causes Py-Ta-GTP complex to dissociate from
the PDEap heterodimer (see Introduction). This state of activation is the State 3 in the
diagram (see Fig. 4.11.). This state of the activation cycle can be reproduced by exposing
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the cGMP depleted ROS membranes to light in the presence of GTPyS without cGMP
added. Again, the resulting ROS membranes were treated with 1% Triton X-100, and the
insoluble material was separated by centrifugation. Analyzing the GARP2 and PDE6
solubility, it is observed that the majority of PDE6, as well as GARP2 are soluble in this
detergent condition (see Fig. 4.12.).
Upon Py-Ta-GTP release, the bound GTP is rapidly hydrolyzed to GDP by the
intrinsic GTPase activity of Ta, which is enhanced by Py and another protein, RGS9.
Only following GTP hydrolysis can Py dissociate from Ta and re-inhibit the catalytic site
of PDE6 (see state 4 of Fig. 4.11.). To reproduce this last step in the PDE6 activation
cycle, ROS membranes were first exposed to light in the presence of GTP. This permits
PDE6 activation, but also inactivation can occur following GTP hydrolysis. Incubating
activated ROS membranes for 2 hours at room temperature, cGMP levels become low
and Py-Ta-GTP dissociates from PDEap. Upon this dissociation GTP is easily
hydrolyzed to GDP, and Py is released. Once again, the membranes are treated with 1%
Triton X-100, the insoluble parts separated by centrifugation, and proteins analyzed by
western blotting or functional assay. PDE6 and GARP2 appear to be equally soluble by
the detergent (see Fig. 4.12.).
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Figure 4.12. Enhanced membrane association of transducin-activated PDE6 is not
accompanied by retention of GARP2 in a membrane-bound state.
ROS membranes (35 pM rhodopsin) were exposed to various treatments, and then mixed
with 1% Triton X-100. The detergent-soluble and detergent-insoluble membrane
fractions were separated by centrifugation. Pellets and supernatants were analyzed for
immunoreactivity and PDE6 activity. (The band observed above 250 kDa marker
represents the p-subunit of the cGMP-gated channel which immunoreacts with the
GARP2 antibody.) This result is representative of two experiments.

Analysis of the membrane fractions under different states of PDE6 activation
reveals that all the GARP2 and some of the PDE6 separate upon activation, particularly
when the GAF domains are occupied by cGMP, and the efficiency of transducin
activation is critical for phototransduction efficacy. In all conditions, some PDE6 and all
GARP2 are soluble in the detergent. [Note that for the GTP only condition, the PDE6
activity analysis shows that there is more soluble PDE6 than membrane-bound, whereas
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the western blot result shows different result that is probably an experimental error due to
inaccurate sample loading on the gel.] These findings could suggest that GARP2 is only
available to regulate PDE6 in its nonactivated state. It is important to mention that the
separation of GARP2 from PDE6 immediately following activation would serve to
maintain the high efficiency of phototransduction activation.

Summary
In this study we examined the mechanism of GARP2 interaction with PDE6. One
site of interaction was determined to be with Py. Following GARP2 addition to the PDE6
holoenzyme, the affinity of Py for PDEap increased, lowering the probability of
spontaneous activation of PDE6 holoenzyme. We determined that GARP2 interacts with
two different regions of Py molecule, binding to both C- and N-terminal domains.
GARP2 was also found to regulate the affinity of the GAF domains for cGMP,
suggesting a direct interaction with the PDEap heterodimer. We also analyzed the
possibility that GARP2 and PDE6 only interact at specific steps during light activation.
Preliminary results showed that upon light activation, PDE6 and GARP2 separate on the
surface of the disk membrane. Further studies are needed to determine all the light
activation conditions that permit PDE6 and GARP2 to come in close proximity. It is also
important to determine whether under the conditions that allow PDE6 and GARP2 to be
in the same membrane fraction, they actually do interact in a physiologically meaningful
way. One of the disadvantages of the detergent solubilization used in this chapter is that it
disrupts the interaction of GARP2 with PDE6.
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CONCLUSIONS AND FUTURE DIRECTIONS

The research presented here examined the regulation of rod photoreceptor PDE6
by the glutamic acid-rich protein 2 (GARP2). First we examined the proteins that interact
with PDE6 during visual transduction. We developed methods to solubilize PDE6 from
the disk membranes, and to isolate and identify the interacting protein complex. We
developed methods to purify PDE6 free of some of the interacting proteins. Also we
developed a method to prepare PDEap heterodimer. We found that one of the proteins
that interact with high affinity with PDE6 is GARP2. The experiments that will solidify
the findings of the PDE6 interacting proteins include: the use of biotinylated antibodies
for detection of association and dissociation of known proteins that interact with PDE6
during various stages of phototransduction, and identification of novel proteins by SDSPAGE followed by mass spectrometry. For an unequivocal determination of PDE6
protein complex, all these experiments have to be pursued using the PDE6 solubilization
methods described in Chapter 2.
After demonstrating that GARP2 is a high affinity PDE6 interacting protein, we
studied the effect that GARP2 has on PDE6 activity. For this reason, we developed
several methods for native GARP2 purification. We showed that native GARP2 is able to
inhibit the PDE6 activity in its nonactivated state, but not when it is activated by either
transducin or by limited trypsinization. This finding suggests that GARP2 has a role in
reducing the spontaneous activation of rod PDE6, reducing therefore the "dark noise" of
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rod photoreceptors, and confering a greater light sensitivity for rods compared to cones.
Also, we demonstrated that GARP2 does not interfere with transducin's ability to activate
PDE6, preserving the high efficiency of activation of visual excitation pathway.
We also found that GARP2 is able to alter the affinity of cGMP for the regulatory
GAF domains of PDE6. It lowers the affinity of the high-affinity GAF domain,
suggesting a direct interaction of GARP2 with PDEap catalytic heterodimer, and also
reverses the Py dependent high-affinity cGMP binding site to a low affinity site. We
determined that GARP2 interacts with PDE6 through multiple sites, primarily at the level
of Py subunit. We also showed that GARP2 increases Py affinity for the PDEap dimer,
determining the lower incidence of spontaneous activation of PDE6.
Because transducin activation of PDE6 is not affected by GARP2, we
hypothesized that GARP2 and PDE6 separate during light activation. We reconstituted
several stages of PDE6 activation with the use of nucleotides, and examined whether
PDE6 and GARP2 were found in the same membrane fraction. Preliminary findings
showed that PDE6 separates from GARP2 into detergent-insoluble membrane domains
upon light activation. Further studies are needed to determine what stages of PDE6
activation-inactivation cycle permit PDE6 and GARP2 to interact. The presence of the
interaction on native membranes will also have to be examined. The methods used for
separating different membrane domains (i.e., lipid rafts)were found to disrupt PDE6GARP2 interactions.
Some of the experiments that will have to be carried out to decipher the
mechanism by which GARP2 interacts and regulates PDE6 during visual transduction
cycle would include the following.
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1. To define the regions of Py responsible for the GARP2 effect on PDE6 catalysis and
regulation. This will first require the examination of GARP2 effect on PDEocP
heterodimer, followed by the analysis of GARP2 effect in the presence of N-and Cterminal Py peptides.
2. To determine the effect of GARP2 on the ability of transducin to activate PDE6 on
GAJRP2-depleted ROS membranes.
3. To determine the affinity and stoichiometry of GARP2 binding to PDE6 catalytic
subunits and Py using analytical ultracentrifugation.
4. To test the possibility of GARP2 being a transducin GTPase accelerating protein.
5. To test GARP2-PDE6 association at different steps of activation-inactivation cycle
without the use of detergents. This will necessitate the use of immunoprecipitating
antibodies.
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